Agent for reducing the useable calorie content of food and for therapeutic reduction of weight, in p

专利摘要:
Agent for reducing the useable calorie content of food and for therapeutic reduction of weight, in particular for use in the case of adiposity (obesity) The invention provides a pharmaceutical composition comprising 5-D-fructose dehy 5 drogenase in combination with one or more enzyme(s) selected from glucose isom erase, invertase, lactase, maltase, alpha-amylase, beta-amylase, glucoamylase, pullulanase, isoamylase, amyloglucosidase and cyclomaltodextrin glucanotrans ferase; but excluding pharmaceutical compositions in which the sole said enzymes present are a combination of 5-D-fructose dehydrogenase and glucose isomerase. 10 Also provided are the use of 5-D-fructose dehydrogenase in treating or preventing adiposity and the treatment of foodstuffs with 5-D-fructose dehydrogenase in order to reduce the calorie content or effective fructose content of the foodstuff.
公开号:AU2013211517A1
申请号:U2013211517
申请日:2013-08-01
公开日:2013-08-22
发明作者:Daniel Henry Wyrobnik；Isaac Harry Wyrobnik
申请人:Pro Natura Gesellschaft fuer Gesunde Ernaehrung mbH；
IPC主号:A61K38-44

专利说明:
1 AUSTRALIA Patents Act 1990 ORIGINAL COMPLETE SPECIFICATION STANDARD PATENT Invention title: Agent for reducing the useable calorie content of food and for therapeutic reduction of weight, in particular for use in the case of adiposity (obesity) This application is a divisional of Australian Patent Application No 2006316815 which is the Australian national phase entry of PCT/EP2006/011231, which claims priority to the following patent applications: Number Country Filing date 60/831,173 United States of America 2006-07-17 10 2006 014 420.1 Germany 2006-03-27 10 2006 013 623.3 Germany 2006-03-22 60/757,413 United States of America 2006-01-10 10 2006 001 016.7 Germany 2006-01-05 10 2005 063 194.0 Germany 2005-12-30 10 2005 061 330.6 Germany 2005-12-20 10 2005 060 767.5 Germany 2005-12-16 10 2005 056 170.5 Germany 2005-11-23 Each of the above applications are herein incorporated by reference in their entireties. The following statement is a full description of this invention, including the best method of performing it known to us: 2 Agent for reducing the useable calorie content of food and for therapeutic reduction of weight, in particular for use in the case of adiposity (obesity) The present invention relates to an agent for reducing the useable calorie content of 5 food. The agent contains a compound that can effect the conversion of fructose to 5 keto-D-fructose. 5-keto-D-fructose cannot be metabolized by the human or animal body and is therefore significantly less caloric than fructose. The present invention also relates to an agent which, in addition to the first compound, contains a com pound that can effect the conversion of glucose to fructose. According the invention 10 the term "agent" includes a pharmaceutical composition, a medical device, a food stuff and a special foodstuff. According to the present invention, the terms "food" and "foodstuff" are used as synonyms. They mean to also include feed in the sense of animal feed. In the con 15 text of this application "special foodstuffs" are foodstuffs for particular nutritional uses, foods for special medical purposes, medical foods, food supplements, dietary supplements, dietetic food supplements, health foods, nutraceuticals, and food additives. In the context of this application the term foodstuff means to include spe cial foodstuffs as used herein, where applicable. 20 Fructose is a ketohexose and is an important energy providing ingredient of food. It is present as a component of many di- and oligosaccharides, as free fructose or as both in numerous foodstuffs. In contrast to glucose, fructose is assimilated into the mucosa cells of the small intestine by eased carrier-mediated diffusion. The enzy 25 matic degradation starts in the liver by the action of the adenosine triphosphate (ATP) dependent fructokinase, whereby fructose is converted to fructose 1 phosphate. In the liver and in the kidneys, fructose 1-phosphate is cleaved to glycer ine aldehyde and dihydroxy acetone phosphate by aldolase B. 30 Food, e.g. fruits and fruit juices, contain a large amount of fructose, but in particular also sucrose, which is cleaved to fructose and glucose in the body. Over the past decades, there has been a dramatic increase in the consumption of free fructose (which is approx. 1.6-fold sweeter than glucose or sucrose) since the cheaper sweetener "high fructose corn syrup" (HFCS) was added to many of our beverages, 35 bakery products and other sweet foodstuffs. Data from the USA show a parallel development between the sharp increase of obesity and the additives of free fruc- 3 tose. In contrast to glucose, fructose is metabolized independently of insulin. Since insulin influences the occurrence of the sensation of satiation indirectly, i.e. fructose does not eliminate the appetite, obesity may easily occur as a result of the extensive use of HFCS as a sweetener. Free fructose in large amounts may also favor hyper 5 tension. Large amounts of free fructose also influence the lipid profile (blood lipids) in an unfavorable way, since they promote the synthesis of lipids and thus increase the postprandial serum triglycerides. Patients with metabolic syndrome should not consume beverages that are sweetened with HFCS or sucrose. Fructose is also discussed as a cause of metabolic syndrome. 10 Thus, fructose is an important source of calories for the human body and must be given special consideration in all efforts to reduce the content of calories in the food. In the following, the term "fructose containing" refers to all substances and foodstuffs that either contain fructose in pure form or from which fructose can be released in 15 the digestive tract. The fructose content of substances and foodstuffs refers to all the fructose in a fructose containing food or substance in whatever form (e.g. also as part of sucrose) it is contained in such a food or substance. Departures from normal weight due to an increase in body weight, primarily in the 20 proportion of fat, are referred to as adiposity (obesity), whereby, normally and in the sense of this invention, four grades are differentiated, namely grade 0 = normal weight, grade I = overweight, grade || = adiposity and grade Ill = extreme adiposity. The individual grades are classified according to the well-known body mass index (BMI). An increase in fatty tissue and thus in body weight above a certain limit leads 25 to an increase in various diseases, such as hypertension, and life expectancy de creases. The number of persons suffering from adiposity grade I to grade Ill has increased constantly in the industrialized countries over the past decades and amounts to 30 to 50 % of the total population at present, depending on the statistic used and definition of the term overweight or obesity. For example, in the Federal 30 Republic of Germany, every second person is overweight (adiposity grade 1) and every sixth person has adiposity grade II or Ill. The number of adipose children is also increasing as a result of poor nutrition and lack of exercise. To date, therapy has been limited to nutrition therapy and, in extreme cases, surgical measures. It is a well-known fact that there is a very large and constantly increasing number of 35 nutrition therapies and diets that generally do not result in lasting success. Even if there is an initial loss in weight, usually this results in the so-called yoyo effect, i.e.
4 the sufferers initially lose weight, but put it back on again after the end or early termination of the diet. Often, in the end the body weight is even higher than prior to the beginning of the diet. Surgical measures, which are only used in particularly severe cases, have the aim of reducing the supply of nutrients or nutrient utilization, 5 and are associated with high operation risks and long-term negative side effects. Nutrient deficits may thus result, due to impairments of absorption and insufficient supply with the food. These relate to vitamins, minerals and proteins. Up to one third of the surgical patients show a folic acid deficiency. In addition, iron, potassium, magnesium and vitamin A deficiencies may occur. 10 The drug therapies known to date for treating adiposity are controversial. Products have often had to be taken off the market due to severe side effects. All drugs that are still available today also have significant, unpleasant and frequent side effects, such as fatty stools, constipation and insomnia. A diet that reliably leads to a sus 15 tainable success and/or a broadly applicable therapy for adiposity in its different types without side effects is not known. Of course, the widespread use of surgical measures does not come into question. It remains to be said that those suffering from obesity and the specialists treating them are confronted by a quite hopeless and frustrating situation for all concerned. 20 An agent that does not have an effect on the body, but on the carbohydrates in the food and that would reduce the useable calorie content in the food would satisfy an extremely widespread and pressing need which has existed for decades. Such an agent would also overcome the prejudice widely held in the specialist world and 25 among those suffering from obesity that a lasting weight reduction or the prevention of an increase in weight is not possible without suffering and without a significant change of nutrition habits. It would mean a dramatic improvement in the options available for the treatment of adiposity. Such an agent would also put an end to the as yet fruitless efforts of the specialist world to find an agent to treat adiposity which 30 can be administered broadly, easily, and long-term, without causing side effects. This would apply all the more to an agent which, in addition, has no negative effects on health. Thus, it is an object of the present invention to provide an agent that significantly 35 reduces the useable calorie content of food, in particular for facilitating the intake of foodstuffs that normally contain fructose also in the case of adiposity, without result- 5 ing in an increase in weight. Further, it is the object of the invention to make it possi ble for persons suffering from adiposity to eat foodstuffs which until now were not allowed to them due to their fructose content or the eating of which was associated with negative effects for the sufferers' health. Another objective is to provide an 5 agent that, after the intake of fructose, can reduce or prevent the associated nega tive effects on weight and/or health, in particular in the case of adiposity. It is also an object of the invention to provide an agent that can prevent persons who up to now have not suffered from adiposity from putting on weight as a result of 10 eating fructose containing substances or foodstuffs. It is thus also an object of the invention to allow persons who are not suffering from adiposity to eat foodstuffs the intake of which would otherwise lead to the risk of weight gain, with the conse quence that these persons might become adipose. 15 These objects are solved by the subject matter as described in 1 to 262. Therefore, the subject matter of the invention is an agent that can solve all of the problems described above. The agent contains 5-D-fructose dehydrogenase (syn. fructose 5 dehydrogenase). The agent according to the present invention brings about the conversion of fructose in the food into 5-keto-D-fructose by dehydrogenation. Thus, 20 the fructose is changed in such a manner that it is no longer available to the metabo lism of the human or animal body. According to another aspect of the invention 5-D-fructose dehydrogenase is used, optionally in combination with glucose isomerase, for treatment of adiposity, for 25 example in the form of a pharmaceutical composition. The treatment of adiposity may be therapeutic or prophylactic. Also, further diseases accompanying adiposity may be treated by making use of the agent according to the invention. According to another aspect of the present invention, the agent is used for lowering 30 the usable calorie content of food. A subject matter of the invention is also an agent that reduces the bioavailability of fructose in the human or animal body with the help of a 5-D-fructose dehydro genase. 35 6 A subject matter of the invention is also an agent that reduces the bioavailability of fructose and glucose in the human or animal body with the help of a 5-D-fructose dehydrogenase in combination with a glucose isomerase. 5 A subject matter of the invention is also an agent that reduces the content of fruc tose in a foodstuff with the help of a 5-D-fructose dehydrogenase. A subject matter of the invention is also an agent that reduces the content of fruc tose and glucose in a foodstuff with the help of a 5-D-fructose dehydrogenase in 10 combination with a glucose isomerase. A subject matter of the present invention is further an agent for reducing the useable calorie content of food which contains a 5-D-fructose dehydrogenase - alone or in combination with a glucose isomerase. 15 The agent according to the invention is suited for the use in the case of adiposity and for the therapeutic or prophylactic treatment of adiposity, possibly accompanied by a further disease usually appearing together with adiposity, including diseases of the cardiovascular system (e.g. hypertension, coronary heart disease, venous insuf 20 ficiency, heart failure, left-ventricular hypertrophy, arteriosclerosis), of metabolic and hormonal function (e.g. diabetes mellitus type 1l, dyslipidemias, hyperuricemia, hyperlipoproteinemia), of the respiratory system (e.g. sleep apnea, Pickwickian syndrome), of the hepatobiliary system (e.g. fatty liver, cholecystolithiasis), of the locomotor system (e.g. gonarthrosis, heel spur, arthrosis of the ankle joint), of the 25 skin (e.g. intertrigo, hirsutism, striae) and for use in the case of neoplasias associ ated with adiposity (e.g. increased risk of endometrial, breast, cervical, gall bladder cancer, etc.), disorders of sexual function (e.g. reduced fertility, complications during birth), psychosocial problems (e.g. reduced self-confidence, social isolation, dis crimination, problems with one's partner or at work), and other problems, such as 30 reduced mobility and staying power, increased risk during operations and more difficult examination conditions. All these diseases and health problems are often associated with adiposity.
7 A further subject matter of the invention is the use of a 5-D-fructose dehydrogenase - alone or in combination with a glucose isomerase - in the case of adiposity or in the case of health problems or diseases associated with adiposity (see above). 5 A further subject matter of the invention is the use of 5-D-fructose dehydrogenase alone or in combination with a further enzyme, preferably together with glucose isomerase - for the manufacture of a medicament (pharmaceutical composition) for the prophylactic or therapeutic treatment of adiposity or diseases associated with adiposity (see above). 10 According to the present invention, a 5-D-fructose dehydrogenase - alone or in combination with a glucose isomerase - may also be used for reducing the useable calorie content in a foodstuff. 15 A 5-D-fructose dehydrogenase, in the context of this application, is an enzyme that can catalyze the dehydrogenation of fructose to 5-keto-D-fructose. A possible method for the production of a 5-D-fructose dehydrogenase is, for exam ple, described in Ameyama et al., Journal of Bacteriology 1981, 814-823, "D 20 Fructose Dehydrogenase of Gluconobacter industrius: Purification, Characterization and Application of Enzymatic Microdetermination of D-Fructose", the content of which is incorporated herein by reference. The practical meaning of such an agent for the reduction of the useable calorie 25 content of food becomes clearer if one considers that fructose is used very widely in the foodstuff industry as a sweetener. In the case of foodstuffs which contain su crose, the content of calories can be reduced by about one half by the use of the agent according to the present invention which contains the enzyme 5-D-fructose dehydrogenase. During digestion, sucrose is enzymatically cleaved to glucose and 30 fructose. The fructose fraction (50 % of the calories contained in sucrose) is then dehydrogenated by said 5-D-fructose dehydrogenase to 5-keto-D-fructose and can therefore no longer be utilized by the body. Glucose is the central carbohydrate of the energy and substrate metabolism. It is the 35 basic component of many polysaccharides (e.g. starch). In the context of this appli cation the term "glucose containing" refers to all substances and foodstuffs that 8 either contain glucose in pure form or from which glucose can be released in the digestive tract. The glucose content of substances and foodstuffs refers to all the glucose in a glucose containing food or substance in whatever form (e.g. also as part of sucrose) it is contained in such a food or substance. 5 Therefore, a further reduction of the calorie content of food may be achieved accord ing to the present invention by an agent that contains glucose isomerase as an additional active ingredient. The invention thus provides compositions and methods that can be used to enable sufferers of Adiposity to ingest fructose-containing foods 10 or fructose- and glucose-containing foods A glucose isomerase in the context of this application is an enzyme that is able to transform glucose into fructose. This conversion can also be brought about, for example, by a xylose isomerase. Thus, such a xylose isomerase is, in the context of 15 this application, also a glucose isomerase. A possible method for the production of a xylose isomerase is, for example, described in Yamanaka, Biochimica et Biophysika Acta, Volume 151 (3), 1968, 670-680, "Purification, Crystallization and Properties of the D-Xylose Isomerase from Lactobacillus brevis" and in Yamanaka, Methods in Enzymology, Volume 41, 1971, 466-471, "D-Xylose Isomerase from Lactobacillus 20 brevis", the contents of which are incorporated herein by reference. Such a combination agent can also be used in the form of two separate dose units, e.g. in two separate tablets, one of which contains glucose isomerase and the other 5-D-fructose dehydrogenase. 25 By combining 5-D-fructose dehydrogenase with the enzyme glucose isomerase, ingested glucose as well as the large amounts of glucose released by the degrada tion of carbohydrates are largely removed from the metabolism of calories by the body. Glucose isomerase has the property of converting glucose into fructose and 30 vice versa with an equilibrium concentration of approximately 50% glucose and 50 % fructose. Such an enzyme combination consisting of 5-D-fructose dehydrogenase and glucose isomerase is ideally suited for considerably reducing the calorie content of, for example starch containing food, such as potatoes. The glucose that is re leased from starch during digestion is transformed into fructose by said glucose 35 isomerase, which is then converted by said 5-D-fructose dehydrogenase into 5-keto D-fructose which is significantly less bioavailable. Thus, the 5-D-fructose dehydro- 9 genase prevents the above described equilibrium from being established. Therefore, glucose isomerase will convert glucose into fructose, which itself will be dehydroge nated by the 5-D-fructose dehydrogenase to 5-keto-D-fructose, until no further glucose is present in the food and food pulp. 5 Also in the case of sucrose, an increased reduction of calories can be achieved with the combination agent. Fructose, which is released from sucrose during digestion, is converted into 5-keto-D-fructose by 5-D-fructose dehydrogenase, as described above. Therefore the glucose isomerase will attempt to re-establish the above de 10 scribed equilibrium by converting glucose into fructose. This conversion process continues until no further glucose is present in the food pulp. In this way, the content of calories of the sucrose containing dishes available to the body is reduced to a greater degree than if 5-D-fructose dehydrogenase is used on its own. 15 The combination agent according to the present invention thus leads to a large proportion of the glucose supplied to the body or released in the digestive tract being converted into fructose which in turn is converted into 5-keto-D-fructose, which is of much less value for the metabolism. 20 In a particularly easy way, the invention facilitates the transformation of fructose in a foodstuff into a form that prevents weight gain and enables weight loss. Thus, the invention also facilitates the intake of foodstuffs by persons who suffer from adipos ity that had to be avoided by the sufferers up to now because of their content of fructose and glucose. Further, the invention allows the intake of fructose and glu 25 cose containing foodstuffs by persons who are not suffering from adiposity, without this leading to negative effects on their weight and/or health. According to the present invention, 5-D-fructose dehydrogenase - alone or in com bination with glucose isomerase - is further mentioned for use in medicine (first 30 medical indication), for example as a pharmaceutical composition. Accordingly, a subject matter of the invention is also a product which consists of 5-D-fructose dehydrogenase - alone or in combination with glucose isomerase - or contains 5-D fructose dehydrogenase - alone or in combination with glucose isomerase - beside one or more other active ingredients for use in a medical method, in particular in a 35 method for the therapeutic treatment of the human or animal body. In the context of this application, a pharmaceutical composition is a product, in particular a substance 10 or a substance mixture, for use in a method for surgical or therapeutic treatment of the human or animal body and in diagnostic methods that are performed on the human or animal body. Thus, in the context of this application, pharmaceutical compositions are also products, in particular substances or substance mixtures, that 5 are meant or suitable for curing, alleviating, preventing or determining adiposity. The term "treating" when used in connection with the foregoing disorders includes amelioration, prevention or relief from the symptoms and/or effects associated with these disorders and includes the prophylactic administration of an enzyme or a 10 mixture thereof to diminish the likelihood or seriousness of the conditions. According to a further aspect of the present invention, a foodstuff is provided which contains 5-D-fructose dehydrogenase - alone or in combination - with glucose isomerase. Further, according to the present invention, a foodstuff is provided which 15 contains 5-D-fructose dehydrogenase - alone or in combination with glucose isom erase - in an amount which is sufficient to convert fructose into 5-keto-D-fructose and which, in addition, contains glucose isomerase in an amount which is effective for transforming glucose into fructose. Such a foodstuff may be produced using a method for treating a foodstuff in which the foodstuff is placed in contact with a 5-D 20 fructose dehydrogenase - alone or in combination with glucose isomerase - under such conditions under which the 5-D-fructose dehydrogenase can dehydrogenate fructose to 5-keto-D-fructose and under which the glucose isomerase can convert glucose into fructose. In contrast to otherwise untreated foodstuffs, such a foodstuff has a reduced content of fructose or, if the agent contains both enzymes, a reduced 25 content of fructose and glucose, and therefore, for the first time, is suitable to be consumed by persons who want to control their weight, including adipose persons. Furthermore, a foodstuff can be prepared by a method in which a 5-D-fructose dehydrogenase is added to the foodstuff - alone or in combination with glucose isomerase - in a manner in which the action of the enzyme or both enzymes only 30 starts after the intake of the foodstuff. Such a foodstuff that contains 5-D-fructose dehydrogenase or 5-D-fructose dehydrogenase and glucose isomerase has the same taste as an untreated foodstuff and is, for the first time, suitable to be con sumed by persons who want to control their weight including adipose persons due to the reduced content of fructose or fructose and glucose which is established after 35 eating.
11 According to a further aspect, according to the present invention, 5-D-fructose dehy drogenase - alone or in combination with glucose isomerase - is provided as a medical device. The subject matter of the invention is accordingly also a medical device that consists of 5-D-fructose dehydrogenase - alone or in combination with 5 glucose isomerase - or contains the 5-D-fructose dehydrogenase - alone or in combination with glucose isomerase - beside one or more other active ingredients. In the following, the invention will be described further in its various aspects. 10 5-D-Fructose dehydrogenase is a compound that has been known for nearly 40 years, but has only been used for analytical purposes to date. Glucose isomerase is a compound that has been known for more than 40 years and has only been used for starch saccharification to date. In the industry, it is used for the conversion of glucose into fructose as well as for the conversion of fructose into glucose. 15 5-D-fructose dehydrogenase, in particular in combination with glucose isomerase, has not been used in the medical/pharmaceutical field to date, in particular not in adiposity in humans or animals. Thus, the invention discloses the first medical indi cation for 5-D-fructose dehydrogenase and the first medical indication for the combi 20 nation of the two enzymes. Until now, the two enzymes have not been used for the therapeutic treatment of the human or animal body or for diagnostic purposes on the human or animal body. The agent according to the present invention may be taken orally prior to meals, 25 immediately before meals, with meals or immediately after meals, so that it can exert its dehydrogenating effect on fructose and optionally converting effect on glucose in the food pulp. The agent according to the present invention may contain the en zyme(s) without further additives. However, it is preferable that the agent according to the present invention further contains additives that are pharmaceutically accept 30 able and/or acceptable for foodstuffs, such as for example extenders, binders, stabilizers, preservatives, flavourings, etc. Such additives are commonly used and well known for the production of pharmaceutical compositions, medical devices, foodstuffs, and special foodstuffs and the person skilled in the art knows which additives in which amounts are suitable for certain presentation forms. The agents 35 according to the present invention may for example contain as additives dicalcium 12 phosphate, lactose, modified starch, microcrystalline cellulose, maltodextrin and/or fibersol. The agents according to the present invention can also be added to a foodstuff 5 before eating. They may even be added to the foodstuff at the production stage, with the aim of developing their effect only after consuming the foodstuff. This may be achieved by microencapsulation, for example. With this, the useable fructose and/or glucose content of the foodstuff may be reduced, without negatively affecting its taste. Therefore, preparations are particularly useful that contain 5-D-fructose dehy 10 drogenase - alone or in combination with glucose isomerase - and which release these enzymes only in the digestive tract of a human or animal or let them become effective in another way, in particular in the stomach or small intestine. Therefore, the invention can be used for example in the production of sweets, fruit preparations (e.g. apple sauce), jam, honey, chocolate and chocolate products, bakery products 15 (e.g. biscuits and cakes), breads, pastas, vegetable dishes, potato dishes, ice cream, cereals, dairy products (e.g. fruit yogurt and pudding), fructose- and/or glu cose-containing beverages, fructose- and/or glucose-containing sauces (e.g. tomato ketchup) and fructose- and/or glucose-containing sweeteners. For dishes that are boiled or baked, the agents according to the present invention could e.g. be mixed 20 into or sprinkled onto them after cooling. Since fructose is widely used as a sweetener in foodstuffs that are especially pro duced for diabetics, the addition of the agents according to the present invention to diabetic food before eating or the addition of the agents according to the present 25 invention during the production of diabetic food allows diabetics who suffer from adiposity to eat diabetic food, such as the above mentioned foodstuffs in their re spective form as diabetic foods. The agent according to the present invention may also be added to a foodstuff, to 30 exert its effect on the fructose originating from another foodstuff and in the case of an agent containing both enzymes also on the glucose originating from another foodstuff after their consumption. An example of this would be the addition of the agent according to the present invention to a spread so that the reduction of the calories that are contained in the bread and that can be utilized by the body occurs 35 after the intake of the bread, without an impairment of taste of the bread. Another 13 example would be mixed spices and mayonnaise, among other things for use with french fries. 5-D-fructose dehydrogenase and the combination agent may also be used in immo 5 bilized form. This is useful for the treatment of liquid foodstuffs. For example, 5-D fructose dehydrogenase can be embedded in a matrix which is permeable for fruc tose. If a fructose containing liquid foodstuff is allowed to flow along the enzyme containing matrix, then fructose is extracted from the foodstuff by the action of the enzyme and converted into 5-keto-D-fructose. 10 A subject matter of the present invention are also agents that in addition to other active ingredients also contain 5-D-fructose dehydrogenase, either alone or in com bination with glucose isomerase. 15 The agent may be formulated in any form which is suitable for the intended route of administration. A preferred route of administration is oral administration. For oral administration, the agent may be formulated for example in the form of capsules (coated or non-coated) containing powder, coated or non-coated pellets, granules or micro-/mini-tablets or in the form of tablets (coated or non-coated) pressed from 20 powder, coated or non-coated pellets, drag6es or micro-/mini-tablets. The agent may also be formulated for example in the form of gel caps or in liquid form as solution, drops, suspension or gel. The agent may also be formulated e.g. as dried or moist oral supplement. The formulation of the agent according to the present invention as powder is particularly suitable for admixing with foodstuff. The powder may be sprin 25 kled onto a meal or mixed into a pulp or beverage. It is particularly beneficial, if the agent offered as bulk powder is packaged in single dosage amounts, such as in single bags or capsules, or if it is provided in a dosing dispenser. For oral administration, the 5-D-fructose dehydrogenase 30 - alone or in combination with glucose isomerase - may be used with acceptable excipients and/or carriers. The total amount of the carrier and/or excipient of an agent containing 5-D-fructose dehydrogenase or 5-D-fructose dehydrogenase and glucose isomerase 35 is preferably between 5 and 99.9 % by weight, more preferably between 10 and 80 14 % by weight and even more preferably between 25 and 60 % by weight of the com position. Suitable excipients and/or carriers include maltodextrin, calcium carbonate, dical 5 cium phosphate, tricalcium phosphate, microcrystalline cellulose, dextrose, rice flour, magnesium stearate, stearic acid, croscarmellose sodium, sodium starch glycolate, crospovidone, sucrose, vegetable gums, lactose, methylcellulose, povidone, car boxymethyl cellulose, corn starch, modified starch, fibersol, gelatine, hydroxypro pylmethyl cellulose and the like (including mixtures thereof). 10 Preferable carriers include calcium carbonate, magnesium stearate, maltodextrin, dicalcium phosphate, modified starch, microcrystalline cellulose, fibersol, gelatine, hydroxypropylmethyl cellulose and mixtures thereof. 15 The various ingredients and the excipient and/or carrier may be mixed and formed into the desired form using common methods well known to the skilled person. The administration form according to the present invention which is suited for the oral route, such as e.g. tablet or capsule, may be coated with a coating which is resistant against low pH values (approximately pH 1 to 2.5) and which dissolves at a pH value 20 of approximately 3.0 to 8.0, preferably at a pH value of 3.0 to 6.5 and particularly preferable at a pH value of 4.0 to 6.0. An optionally used coating should be in accor dance with the pH optimum of the enzyme used and its stability at pH values to which the formulation will be exposed. Also a coating may be used which is not resistant to low pH values but which delays the release of the enzyme at low pH 25 values. It is also possible to prepare the agent according to the present invention as coated (see above) pellets, granules or micro-/mini-tablets which can be filled into coated or non-coated capsules or which can be pressed into coated or non-coated tablets. Suitable coatings are, for example, cellulose acetate phthalate, cellulose derivates, shellac, polyvinylpyrrolidone derivates, acrylic acid, polyacrylic acid deri 30 vates and polymethyl methacrylate (PMMA), such as e.g. Eudragit@ (from R6hm GmbH, Darmstadt, Germany), in particular Eudragit@ L30D-55. The coating Eudragit@ L30D-55 is dissolved, for example, at a pH value of 5.5 and higher. If it is desired to release the enzyme already at a lower pH value, this may be achieved e.g. by the addition of sodium hydroxide solution to the coating agent Eudragit@ 35 L30D-55, because in this case carboxyl groups of the methacrylate would be neu tralised. Therefore, this coating will be dissolved, for example, already at a pH value 15 of 4.0 provided that 5 % of the carboxyl groups are neutralised. The addition of about 100 g of 4 % sodium hydroxide solution to 1 kg of Eudragit@ L30D-55 would result in a neutralisation of about 6 % of the carboxyl groups. Further details about formulation methods and administration methods can be found in the 21st edition of 5 "Remington: The Science & Practice of Pharmacy", published 2005 by Lippincott, Williams & Wilkins, Baltimore, USA, in the Encyclopedia of Pharmaceutical Technol ogy (Editor James Swarbrick) and in Prof. Bauer "Lehrbuch der Pharmazeutischen Technologie", 18th edition, published 2006 by Wissenschaftliche Verlagsgesellschaft (ISBN 3804-72222-9). The contents of these documents are incorporated herein by 10 reference. Other suitable acceptable carriers or adjuvants for use in the present invention include, but are not restricted to water, mineral oil, ethylene glycol, propylene glycol, lanolin, glyceryl stearate, sorbitan stearate, isopropyl myristate, isopropyl palmitate, 15 acetone, glycerine, phosphatidylcholine, sodium cholate or ethanol. The compositions for use in the present invention may also comprise at least one co-emulsifying agent which includes but is not limited to oxyethylenated sorbitan monostearate, fatty alcohols, such as stearyl alcohol or cetyl alcohol, or esters of 20 fatty acids and polyols, such as glyceryl stearate. The agents according to the present invention may be provided in a stabilized form. Generally, stabilization methods and procedures which may be used according to the present invention include any and all methods for the stabilization of chemical or 25 biological material which are known in the art, comprising e.g. the addition of chemi cal agents, methods which are based on temperature modulation, methods which are based on irradiation or combinations thereof. Chemical agents that may be used according to the present invention include, among others, preservatives, acids, bases, salts, antioxidants, viscosity enhancers, emulsifying agents, gelatinizers, and 30 mixtures thereof. Usually, the industrial production of enzymes is performed in a technical fermenta tion way using suitable microorganisms (bacteria, moulds, fungi). Usually the strains are recovered from natural ecosystems according to a special screening protocol, 35 isolated as pure cultures as well as improved in their properties with respect to the 16 enzyme spectrum and biosynthesis performance (volume/time yield). Enzyme production may also be carried out by methods developed in the future. 5-D-fructose dehydrogenase is commercially available (e.g. Sigma-Aldrich or To 5 yobo Enzymes, Japan) and is usually prepared in a microbiological way with the help of the microorganism Gluconobacter industrius. Glucose isomerase is also commercially available (e.g. Sigma-Aldrich or Novozymes A/S, Denmark) and usu ally prepared in a microbiological way with the help of the microorganism Streptomy ces murinus. However, the invention is not limited to the enzymes that are commer 10 cially available at the moment, but generally relates to enzymes that can catalyze the conversion of fructose - specifically or non-specifically - to 5-keto-D-fructose, and of glucose - specifically or non-specifically - to fructose. A person skilled in the art can prepare suitable further enzymes by conventional methods, for example by mutagenesis of the gene encoding 5-D-fructose dehydrogenase which is present in 15 Gluconobacter industrius or by mutagenesis of the gene encoding glucose isom erase in streptomyces murinus. The enzymes may also be prepared with the help of other microorganisms, such as fungi, in sufficient amounts and the required purities, also by the use of the genetic engineering methods which are presently known or may be developed in the future. For example, if it is desired to produce the enzymes 20 with other microorganisms, then the genetic information of a microorganism which has been found initially by extensive screening and which has been proven to be a suitable source of the enzyme with the desired properties can be transferred to a microorganism which is normally used for the production of enzymes. Also the modification of the enzyme(s) and the production of the enzyme(s) by means of 25 methods which are presently known or may be developed in the future in the area of industrial enzyme development and enzyme production, such as genetic engineer ing, is possible. The use and the manner of performing all these methods for devel oping and producing the enzyme(s) with the desired purities and activities and with the desired properties, in particular with respect to the stability of the enzyme(s) at 30 various pH values, regarding the optimum of the pH value, the stability at various temperatures and temperature optimum, are well known to a person skilled in the art. The explanations in chapter 2 (page 82 to page 130) of the textbook "Lebensmit tel-Biotechnologie und Ernshrung" of Heinz Ruttloff, JCirgen Proll and Andreas Leuchtenberger, published by Springer Verlag 1997 (ISBN 3-540-61135-5) describe 35 these methods in detail. These methods are also described in "Advances in Fungal Biotechnology for Industry, Agriculture, and Medicine" by Jan S. Tkacz, Lene 17 Langeand (published in 2004, ISBN 0-306-47866-8), in "Enzymes in Industry: Pro duction and Applications" by Wolfgang Aehle (Editor), published in 2004, ISBN 3527295925 and in "Microbial Enzymes and Biotransformations" by Jose-Luis Barredo (Humana Press 2005, ISBN 1588292533). These documents are herewith 5 incorporated into the patent application by reference. All this also applies to the enzymes mentioned below that can optionally be added to the agent according to the present invention. The activity of 5-D-fructose dehydrogenase is defined in units (assay available e.g. 10 from Sigma-Aldrich), whereby one unit is the amount of 5-D-fructose dehydrogenase that converts one micromole of D-fructose to 5-keto-D-fructose per minute at pH 4.5 and 37'C. Generally, the activity of 5-D-fructose dehydrogenase per dose unit should be between 10 and 5 million units, preferably between 25 and 2.5 million units and particularly preferably between 50 and 1 million units. 15 In the case of the combination agent according to the present invention which also contains glucose isomerase, the composition should contain glucose isomerase in an amount of 0.01 to 100,000 GIU, preferably of 0.05 to 10,000 GIU and particularly preferably of 0.1 to 1,000 GIU per dose unit. One unit of this enzyme is defined as a 20 glucose isomerase unit (GIU). One GIU converts 1 g of glucose into fructose at a pH value of 6.0 and at a temperature of 370C from a solution of initially 10 % (percent by weight, i.e. 10 g of glucose + 90 g of water) in 5 minutes. The wide range of the above mentioned dosages may be explained by the fact that 25 the agent according to the present invention can be applied for many uses, such as the different categories of adiposity and its accompanying and resulting diseases, or simply the effort of persons of normal weight to limit the intake of calories for pre venting weight gain. Furthermore, the different dosages also result from the fact that strongly varying amounts of fructose and glucose are administered to the body, 30 depending on the respective food. The agent according to the present invention may comprise one or more additional enzymes, such as invertase (syn. beta-fructofuranosidase or beta-fructosidase), lactase (syn. beta-galactosidase), maltase (syn. alpha-glucosidase), alpha-amylase, 35 beta-amylase, glucoamylase, pullulanase, isoamylase, amyloglucosidase, cyclomal todextrin glucantransferase (CGTase). These enzymes have the property of releas- 18 ing fructose and/or glucose from fructose and/or glucose containing substances and foodstuffs - alone or in combination with one or more of these enzymes -, whereby the enzymes pullulanase and isoamylase also increase the efficiency of glucoamy lase and beta-amylase. All these enzymes are commercially available (e.g. BioCat 5 Inc., Troy, USA or Novozymes A/S, Denmark or Amano Enzymes Inc., Japan or Sigma-Aldrich) and, up to now, have never been used in combination with 5-D fructose dehydrogenase - alone or in combination with glucose isomerase - in the medical/pharmaceutical field, in particular not in the case of adiposity. Thus this application discloses the first medical indication for 5-D-fructose dehydrogenase 10 alone or in combination with glucose isomerase - in combination with any or all of these enzymes. Examples for agents according to the present invention include: 5-D-fructose dehydrogenase in combination with invertase, or 5-D-fructose dehydro genase in combination with glucose isomerase and invertase, or 5-D-fructose dehy drogenase in combination with glucose isomerase and lactase and invertase, still 15 further 5-D-fructose dehydrogenase in combination with glucose isomerase, Inver tase, alpha amylase, beta amylase, glucoamylase, maltase, iso-amylase and pullu lanase (combination of 9 enzymes), or 5-D-fructose dehydrogenase in combination with glucose isomerase, alpha amylase, beta amylase, glucoamylase, maltase, iso amylase and pullulanase as well as invertase and lactase (combination of 10 en 20 zymes). For example, said invertase can release glucose and fructose from e.g. sucrose and said lactase can release glucose from lactose. Beta-amylase breaks down e.g. 1,4 alpha bonds in starch, starting at the non-reducing end of the polysaccharide chain 25 with cleaving of maltose, and glucose is released by the action of maltase on mal tose. By the addition of one or more of these enzymes to the agent according to the present invention, the endogenic release of fructose and/or glucose from fructose and/or glucose-containing substances or foodstuffs, in particular from sucrose and starch, may also be promoted and accelerated, so that the conversion of fructose 30 into 5-keto-D-fructose which is catalyzed by 5-D-fructose dehydrogenase and/or the conversion of glucose to fructose, which is effected by glucose isomerase, may occur earlier. Therefore, the addition of one or more of these enzymes to the agent according to the present invention may have the benefit of reducing the required amount of 5-D-fructose dehydrogenase and glucose isomerase. 35 19 The activity of invertase is measured in Sumner units (SU, assay available e.g. from Bio-Cat Inc., Troy, Virginia, USA). An SU is defined as the amount of the enzyme which converts 1 mg of sucrose into glucose and fructose under standard test condi tions within 5 minutes at 200C and a pH value of 4.5. If the agent according to the 5 present invention also contains invertase, the activity of the invertase per dose unit should be between 50 and 250,000 SU, preferably between 100 and 150.000 SU and particularly preferably between 150 and 100,000 SU per dose unit. The activity of lactase is given in Food Chemical Codex (FCC) units (assay is pub 10 lished in the Food Chemical Codex, fifth edition, and also available e.g. from Bio Cat Inc. Troy, Virginia or Amano Enzymes, Japan or from Sigma Aldrich). If the agent according to the present invention also contains lactase, the activity of the lactase per dose unit should be between 50 and 200,000 FCC units, preferably between 100 and 100,000 FFC units and particularly preferably between 150 and 50,000 FCC 15 units. The activity of maltase is defined in units, wherein one unit is the amount of maltase which will convert maltose to D-glucose at a rate of one milligram per minute at 37 0 C and a pH of 4.0 in a 10% maltose solution by weight. 20 Where the agent according to the present invention also contains maltase, the activity per dose unit should be between 100 and 100,000 units, preferably between 200 and 50,000 units and particularly preferably between 500 and 20,000 units. 25 Also for the other enzymes mentioned, the standard test conditions and the way in which the enzyme activities are to be determined are known and can be read up by specialists in the field. Insofar as one or more of the optional enzymes are added to the agent according to 30 the present invention, they - as is the case for the 5-D-fructose dehydrogenase and the glucose isomerase - should be used in sufficient amounts so that they can de velop a sufficient enzyme activity for the intended purpose, e.g. sufficient invertase, so that an amount of sucrose usually ingested with a normal meal (e.g. 15 g) can be cleaved, and/or lactase, so that an amount of lactose usually ingested with a normal 35 meal (e.g. 10 g) can be cleaved.
20 The enzymes used can be for example in solid form, e.g. as crystalline or amor phous granules or powders, as a paste or as a liquid, as well as in other forms. In some embodiments, the enzyme is a free enzyme. In other embodiments, the en zyme may e.g. be immobilized on substrate, which can be powderized if necessary 5 before the enzyme is used in accordance with the invention. If the agent according to the present invention is added to a foodstuff before eating or during production, the activity of 5-D-fructose dehydrogenase should be between 10 and 250,000 units, preferably between 25 and 150,000 units and particularly 10 preferably between 50 and 100,000 units per gram fructose in the foodstuff. If the agent also contains glucose isomerase and the agent according to the present invention is added to a foodstuff before eating or during production, the activity of glucose isomerase should be between 0.01 and 20,000 units, preferably between 0.05 and 10,000 units and particularly preferably between 0.1 and 1000 units per 15 gram glucose in the foodstuff. If the agent according to the present invention is added to a foodstuff before eating or during production and if the agent contains 5-D-fructose dehydrogenase and glucose isomerase, the activity of 5-D-fructose dehydrogenase should be between 20 10 and 250,000 units, preferably between 25 and 150,000 units and particularly preferably between 50 and 100,000 units per gram of fructose and glucose com bined contained in the foodstuff. It may be advantageous to add an electron acceptor to the agent according to the 25 present invention at e.g. a ratio (acceptor : substrate) of 1:1 to 1:1,000, preferably at a ratio of 1:2 to 1:200, particularly preferably at a ratio of 1:10 to 1:50. Examples of suitable acceptors which may be used include NAD+, NADP+, FAD+, vitamins, such as vitamin C, vitamin E or vitamin A, ferricyanide, ketones, aldehydes, 2,6 dichlorophenolindophenol, phenazine methosulfate, nitroblue tetrazolium (including 30 mixtures thereof), but are not limited thereto. The physiologically present electrolytes should be sufficient for the function of the glucose isomerase. But it may also be advantageous to add electrolytes to the agent according to the 35 present invention, e.g. in an amount of 0.0001 % to 0.1 % of the substrate (glucose). Examples of the electrolytes include, but are not limited to, MgSO4, Na2CO3, Na- 21 HCO3, NaOH, Na2SO4, MgCO3, H2SO4, NaS2O3, NaS2O5 (including mixtures thereof). It may also be advantageous to add metal ions, in particular cations, such as Mn2+, 5 Mg2+, Ca2+, Zn2+, Fe2+, Co2+ or Cu2+, including mixtures thereof, to the agent according to the present invention, namely preferably in a molar ratio of 10-6 to 10 2. For the above mentioned (xylose) glucose isomerase which is described by Ya manaka, in particular Mn2+ is a suitable cation. 10 Capsule sizes mentioned below refer to the size definitions used by Capsugel Bel gium BVBA, Bornem, Belgium. The size of the capsules should be chosen according to the specific formulation of the agent. A composition according to the present invention for the production of capsules (for 15 example of size 00) may consist of 370 mg of 5-D-fructose dehydrogenase with an activity of 90 units/mg and 100 mg of dicalcium phosphate per capsule. Another example for a dosage form according to the present invention consists of capsules (size 1) that contain 110 mg of 5-D-fructose dehydrogenase with an activity 20 of 500 units/mg as well as 50 mg of invertase with an activity of 200 SU units/mg as well as 50 mg of maltase with an activity of 200 units/mg and 90 mg of maltodextrin. Another example for the dosage form according to the present invention consists of capsules of size 00 which contain 200 mg of 5-D-fructose dehydrogenase with an 25 activity of 500 units/mg as well as 100 mg of invertase with an activity of 200 SU units/mg as well as 150 mg of dicalcium phosphate. In the case of a combination agent in which 5-D-fructose dehydrogenase and glu cose isomerase are used, a capsule of size 0 may contain 250 mg of 5-D-fructose 30 dehydrogenase with an activity of 90 units/mg and 20 mg of glucose isomerase with an activity of 1 GIU/mg and 50 mg dicalcium phosphate. A further example of a combination preparation with 5-D-fructose dehydrogenase and glucose isomerase for the production of capsules of size 00 may contain 370 mg 35 of 5-D-fructose dehydrogenase with an activity of 90 units/mg, 30 mg of glucose isomerase with an activity of 1 GIU/mg and 70 mg of dicalcium phosphate.
22 A further example of a combination preparation with 5-D-fructose dehydrogenase and glucose isomerase for the production of capsules of size 00 may contain 110 mg of 5-D-fructose dehydrogenase with an activity of 500 units/g, 50 mg of glucose 5 isomerase with an activity of 1 GIU/mg, 100 mg of invertase with an activity of 200 SU units/mg, 90 mg of lactase with an activity of 100 FCC units/mg and 120 mg of dicalcium phosphate. A further example of a combination preparation with 5-D-fructose dehydrogenase 10 and glucose isomerase for the production of capsules (e.g. of size 3) may consist of 55 mg of 5-D-fructose dehydrogenase with an activity of 1000 units/mg, 50 mg of glucose isomerase with an activity 1 GIU/mg and 55 mg of dicalcium phosphate per capsule. 15 A further example for a dosage form according to the present invention consists of capsules (size 00) that contain 165 mg of 5-D-Fructose dehydrogenase with an activity of 1000 units/mg, 150 mg of glucose isomerase with an activity of 1 GIU/mg and 155 mg of dicalcium phosphate per capsule. 20 The invention may for example contain between 10 and 5 million units of 5-D-fructose dehydrogenase per dose unit. In addition, suitable additives in the required amount may be used. The invention may, in addition, contain glucose isomerase, for example between 0.01 and 100,000 GIU (= glucose isomerase units) per dose unit. 25 The invention may be provided for medical purposes and non-medical purposes, e.g. as a pharmaceutical composition, medical device, foodstuff or special foodstuff. With the agents according to the present invention the content of calories of carbo 30 hydrate containing food that can be utilized by the body can be reduced to such a degree that a marked weight loss can be achieved or a weight gain can be pre vented despite the intake of carbohydrate rich food. The agents according to the present invention are thus suitable for use in methods for the therapeutic treatment of the human or animal body in which a limitation or reduction of the intake of food 35 calories originating from carbohydrates is intended, e.g. in the case of the therapy of diseases of the cardiovascular system (e.g. hypertension, coronary heart disease, 23 venous insufficiency, heart failure, left-ventricular hypertrophy, arteriosclerosis), of metabolic and hormonal function (e.g. diabetes mellitus type 1l, dyslipidemias, hype ruricemia, hyperlipoproteinemia), of the respiratory system (e.g. sleep apnea, Pick wickian syndrome), of the hepatobiliary system (e.g. fatty liver, cholecystolithiasis), 5 of the locomotor system (e.g. gonarthrosis, heel spur, arthrosis of the ankle joint), of the skin (e.g. intertrigo, hirsutism, striae), in the therapy of neoplasias (e.g. in creased risk of endometrial, breast, cervical, gall bladder cancer, etc.), in the therapy of disorders of sexual function (e.g. reduced fertility, complications during birth), in the therapy of psychosocial problems (e.g. reduced self-confidence, social isolation, 10 discrimination, problems with one's partner or at work) and other problems, such as reduced mobility and staying power, increased risk during operations and more difficult examination conditions. All these diseases and health problems are often associated with adiposity. 15 The agents according to the present invention are in particular suitable for use in the case of adiposity and for the therapeutic treatment of adiposity. In the following embodiments and claims, the term 'fructose equivalent-containing" refers to all substances and foodstuffs that contain fructose (a) as fructose per se, 20 (b) in a form from which fructose can be released in the digestive tract (e.g. by cleavage as fructose from a saccharide chain containing at least two saccharide monomers), (c) in a form that can be converted to fructose, e.g. as glucose per se, or (d) in a form that can be released in the digestive tract and converted to fructose, e.g. as a saccharide chain containing at least two saccharide monomers, at least 25 one of which can be cleaved from the saccharide chain as glucose. In the following embodiments and claims, the term "total fructose" refers to the total content of fructose in a foodstuff (a) as fructose per se, (b) in a form from which fructose can be released in the digestive tract (e.g. by cleavage as fructose from a 30 saccharide chain containing at least two saccharide monomers), (c) in a form that can be converted to fructose, e.g. as glucose per se, or (d) in a form that can be released in the digestive tract and converted to fructose, e.g. a saccharide chain containing at least two saccharide monomers, at least one of which can be cleaved from the saccharide chain as glucose. 35 24 In the following embodiments and claims, the term "effective fructose content" of an item refers to the effective amount of total fructose in that item, taking into account the prior action of fructose converting enzymes that have been added to the item or the future action of fructose converting enzymes that have been added to the item. 5 Thus, for example, a foodstuff having a given fructose content and having microen capsulated 5-D-fructose dehydrogenase incorporated therein will have a lower effective fructose content than a foodstuff which lacks the microencapsulated 5-D fructose dehydrogenase but is otherwise identical, since release of the 5-D-fructose dehydrogenase after ingestion will result in at least a portion of the fructose in the 10 foodstuff being converted to 5-keto D-fructose. The following are embodiments of the invention: Embodiments 15 1. A 5-D-fructose dehydrogenase, optionally in combination with one or more enzyme(s) selected from glucose isomerase, invertase, lactase, maltase, al pha-amylase, beta-amylase, glucoamylase, pullulanase, isoamylase, amyloglu cosidase and cyclomaltodextrin glucanotransferase, for use in medicine. 20 2. A pharmaceutical composition comprising 5-D-fructose dehydrogenase option ally in combination with one or more enzyme(s) selected from glucose isom erase, invertase, lactase, maltase, alpha-amylase, beta-amylase, glucoamy lase, pullulanase, isoamylase, amyloglucosidase and cyclomaltodextrin glu 25 canotransferase. 3. The composition of matter according to 1 and/or 2, including one or more enzyme(s) protected by a coating to be stable at pH values of less than 4, pref erably less than 3. 30 4. The composition of matter according to one or more of 1 to 3 in a form for oral administration. 5. The composition of matter according to one or more of 1 to 4 in a form suited to 35 be added to food at the production stage of the same and/or before eating.
25 6. A medical device comprising 5-D-fructose dehydrogenase optionally in combi nation with one or more enzyme(s) selected from glucose isomerase, invertase, lactase, maltase, alpha-amylase, beta-amylase, glucoamylase, pullulanase, isoamylase, amyloglucosidase and cyclomaltodextrin glucanotransferase. 5 7. The medical device according to 6 including one or more enzyme(s) protected by a coating to be stable at pH values of less than 4, preferably less than 3. 8. The medical device according to 6 and/or 7 in a form for oral administration. 10 9. The medical device according to one or more of 6 to 8 in a form suited to be added to food at the production stage of the same and/or before eating. 10. A foodstuff comprising 5-D-fructose dehydrogenase in combination with inver 15 tase and/or maltase and/or lactase. 11. A special foodstuff comprising 5-D-fructose dehydrogenase optionally in com bination with one or more enzyme(s) selected from glucose isomerase, inver tase, lactase, maltase, alpha-amylase, beta-amylase, glucoamylase, pullu 20 lanase, isoamylase, amyloglucosidase and cyclomaltodextrin glucanotrans ferase. 12. The special foodstuff according to 11 including one or more enzyme(s) pro tected by a coating to be stable at pH values of less than 4, preferably less 25 than 3. 13. The special foodstuff according to 11 and/or 12 in a form for oral administration. 30 14. The foodstuff according one or more of 11 to 13 in a form suited to be added to food at the production stage of the same and/or before eating. 15. The composition of matter according to one or more of 1 to 5, the medical device according to one or more of 6 to 9 or the foodstuff 35 according one or more of 11 to 14 comprising 5-D-fructose dehydrogenase in combination with glucose isomerase.
26 16. A use of 5-D-fructose dehydrogenase, optionally in combination with one or more enzyme(s) selected from glucose isomerase, invertase, lactase, maltase, alpha-amylase, beta-amylase, glucoamylase, pullulanase, isoamylase, amy 5 loglucosidase and cyclomaltodextrin glucanotransferase for production of an agent, preferably a pharmaceutical composition, for the curative or prophylactic treatment of adiposity. 17. The use according to 16, wherein adiposity is accompanied by disturbances of 10 the cardiovascular system and/or of the metabolic and hormone based function and/or of the respiratory system and/or of the hepatobiliary system and/or dis turbances of the locomotor system and/or diseases of the skin and/or neopla sias and/or disorders of the sexual function and/or psychosocial problems and/or reduced mobility and staying power and/or an increased operation risk 15 and/or more difficult examination conditions. 18. The use according to 17, wherein the disturbances of the cardiovascular sys tem are hypertension, coronary heart disease, venous insufficiency, heart fail ure, left-ventricular hypertrophy and/or arteriosclerosis. 20 19. The use according to 17, wherein the disturbances of the metabolic or hormo nal function are diabetes mellitus type 1l, dyslipidemias, hyperuricemia and/or hyperlipoproteinemia. 25 20. The use according to 17, wherein the disturbances of the respiratory system are sleep apnea and/or the Pickwickan syndrome. 21. The use according to 17, wherein the disturbances of the hepatobiliary system are fatty liver and/or cholecystolithiasis. 30 22. The use according to 17, wherein the disturbances of the locomotor system are gonarthrosis, heel spur and/or arthrosis of the ankle joint. 23. The use according to 17, wherein the disturbances of the skin are intertrigo, 35 hirsutism and/or striae.
27 24. The use according to 17, wherein in the case of neoplasias these are endo metrial, mama, cervix and/or gall bladder carcinoma. 25. The use according to 17, w herein the disorders of the sexual function are 5 reduced fertility and/or an increased risk of complications in the case of birth. 26. The use according to 17, wherein the psychosocial problems are reduced self confidence, social isolation, discrimination and/or, problems with the partner and/or at the job. 10 27. A use of 5-D-fructose dehydrogenase, optionally in combination with one or more enzyme(s) selected from glucose isomerase, invertase, lactase, maltase, alpha-amylase, beta-amylase, glucoamylase, pullulanase, isoamylase, amy loglucosidase and cyclomaltodextrin glucanotransferase for production of an 15 agent, preferably a pharmaceutical composition, for lowering the bioavailability of fructose and/or glucose in the human or animal body. 28. A use of 5-D-fructose dehydrogenase, optionally in combination with one or more enzyme(s) selected from glucose isomerase, invertase, lactase, maltase, 20 alpha-amylase, beta-amylase, glucoamylase, pullulanase, isoamylase, amy loglucosidase and cyclomaltodextrin glucanotransferase for production of an agent, preferably a pharmaceutical composition, for lowering the content of fructose and/or glucose in a foodstuff. 25 29. A use of 5-D-fructose dehydrogenase, optionally in combination with one or more enzyme(s) selected from glucose isomerase, invertase, lactase, maltase, alpha-amylase, beta-amylase, glucoamylase, pullulanase, isoamylase, amy loglucosidase and cyclomaltodextrin glucanotransferase for production of an agent, preferably a pharmaceutical composition, for lowering the usable calorie 30 content of food. 30. The use according to one or more of 16 to 29 wherein the agent, preferably the pharmaceutical composition, is in a form for oral administration. 35 31. The use according to one or more of 16 to 30, according to which at least two enzymes are present.
28 32. The use according to 31, according to which the two enzymes are 5-D-fructose dehydrogenase and glucose isomerase. 5 33. The use according to one or more of 16 to 32, wherein the agent is selected from a pharmaceutical composition, a medical device, a foodstuff or a special foodstuff. 34. The use according to one or more of 16 to 33, wherein the enzymes are protected by a coating to be stable at pH values of less than 4, preferably less than 3. 10 35. The use according to one or more of 16 to 34, wherein the agent is in a form for oral use. 36. The use according to one or more of 16 to 35, wherein the product is suited to be 15 added to food at the production stage of the same and/or before eating. 37. The use according to one or more of 16 to 33, wherein the product is in a form for use in immobilised form. 20 38. A process for the treatment of a foodstuff, comprising the steps of contacting the foodstuff with a 5-D-fructose dehydrogenase optionally in combination with one or more enzyme(s) selected from glucose isomerase, invertase, lactase, mal tase, alpha-amylase, beta-amylase, glucoamylase, pullulanase, isoamylase, amyloglucosidase and cyclomaltodextrin glucanotransferase, and initiating the 25 reduction of the fructose content and optionally the reduction of the glucose content of the foodstuff. 39. The process according to 37, wherein as a further step prior to the initiation ingestion of the foodstuff takes place 30 40. A mammalian-ingestible composition of matter which comprises an enzyme that converts D-fructose into a form that is biologically inactive in a chosen mam malian body or a mixture of such enzymes.
29 41. A mammalian-ingestible composition of matter which comprises an enzyme that converts D-fructose into a form that cannot be digested in a chosen mammalian digestive tract. 5 42. A mammalian-ingestible composition of matter which comprises an enzyme that converts D-fructose into a form that is not metabolizable in a chosen mammal ian body. 43. A mammalian-ingestible composition of matter according to any of 40 to 42 10 wherein said chosen mammalian body is a human body. 44. A mammalian-ingestible composition of matter according to any of 40 to 42 wherein said chosen mammalian body is a non-human body. 15 45. A composition of matter according to any of 40 to 44 wherein said form is 5-keto D-fructose. 46. A composition of matter according to any of 40 to 45 wherein said enzyme is 5 D-fructose dehydrogenase. 20 47. A composition of matter according to any of 40 to 46 which is a human dietary supplement or a pharmaceutical composition. 48. A composition of matter according to any of 40 to 46 which is an animal dietary 25 supplement or a veterinary composition. 49. A composition of matter according to any of 40 to 46 which is a special foodstuff. 50. A composition of matter according to 47 or 49 which further comprises at least 30 one pharmaceutically or dietarily acceptable carrier or excipient. 51. A composition of matter according to 48 which further comprises at least one veterinarily acceptable carrier or excipient. 35 52. A composition of matter according to any of 47 to 51 wherein said composition of matter contains said enzyme in microencapsulated form.
30 53. A composition of matter according to any of 47 to 52 wherein said composition of matter is in the form of a capsule or tablet. 5 54. A composition of matter according to any of 47 to 52 wherein said composition of matter is in the form of granules or pellets. 55. A composition of matter according to any of 47 to 51 wherein said composition of matter is in the form of a solution. 10 56. A composition of matter according to any of 47 to 52 wherein said composition of matter is in the form of a liquid. 57. A composition of matter according to any of 47 to 52 wherein said composition of 15 matter is in the form of a gel or suspension. 58. A composition of matter according to 57 wherein said composition of matter is in the form of a gelcap. 20 59. A composition of matter according to any of 47 to 52 wherein said composition of matter is in the form of a powder. 60. A composition of matter which is microencapsulated enzyme 5-D-fructose dehy drogenase. 25 61. A composition of matter according to any of 40 to 60 wherein said composition is adapted to be mixed with a food. 62. A composition of matter comprising the enzyme 5-D-fructose dehydrogenase 30 admixed with a mammalian-ingestible substance. 63. A composition of matter according to 62 wherein said mammalian-ingestible substance is a human-ingestible substance. 35 64. A composition of matter according to 62 wherein said mammalian-ingestible substance is an animal-ingestible substance.
31 65. A composition of matter according to 62 or 63 wherein said mammalian ingestible substance is a pharmaceutically or dietarily acceptable carrier or ex cipient. 5 66. A composition of matter according to 62 or 64 wherein said mammalian ingestible substance is a veterinarily acceptable carrier or excipient. 67. A composition of matter according to any of 62 to 64 wherein said 5-D-fructose 10 dehydrogenase is microencapsulated. 68. A composition of matter according to any of 40 to 67 wherein said enzyme con stitutes between 5 and 99.9% by weight of the composition of matter. 15 69. A composition of matter according to 68 wherein said enzyme constitutes be tween 10 and 80% by weight of the composition of matter. 70. A composition of matter according to 68 wherein said enzyme constitutes be tween 25 and 60% by weight of the composition of matter. 20 71. A composition of matter according to any of 40 to 70, wherein said composition of matter is in unit dosage form and said unit dosage contains between 10 and 5 million units of 5-D-fructose dehydrogenase activity. 25 72. A composition of matter according to 71 wherein said unit dosage contains between 25 and 2.5 million units of 5-D-fructose dehydrogenase activity. 73. A composition of matter according to 71 wherein said unit dosage contains between 50 and 1 million units of 5-D-fructose dehydrogenase activity. 30 74. A composition of matter according to any of 40 to 73 wherein said composition of matter comprises a coating which dissolves in an aqueous medium at a pH of between 3.0 and 8.0. 35 75. A composition of matter according to 74 wherein said coating does not dissolve in an aqueous medium at a pH of below 3.0.
32 76. A composition of matter according to 74 wherein said coating does not dissolve in an aqueous medium at a pH below 4.0. 5 77. A composition of matter according to any of 74 to 76 wherein said coating does not dissolve in an aqueous medium at a pH above 6.5. 78. A composition of matter according to 77 wherein said coating does not dissolve in an aqueous medium at a pH above 6.0. 10 79. A composition of matter according to any of 40 to 73 wherein said composition of matter is a slow-release or extended-release formulation. 80. A composition of matter according to 79 wherein said slow-release or extended 15 release formulation comprises a slow-release or extended-release coating. 81. A composition of matter according to any of 40 to 80 wherein said composition of matter further comprises a second enzyme. 20 82. A composition of matter according to 81 wherein said second enzyme is capable of cleaving fructose or glucose from a sugar that contains at least two saccha ride monomers. 83. A composition of matter according to 82 wherein said second enzyme is inver 25 tase or maltase. 84. A composition of matter according to 83 wherein said second enzyme is inver tase, said composition of matter is in unit dosage form, and each unit dosage contains between 50 and 250,000 Sumner units of invertase activity. 30 85. A composition of matter according to 84 wherein each unit dosage contains between 100 and 150,000 Sumner units of invertase activity. 86. A composition of matter according to 84 wherein each unit dosage contains 35 between 150 and 100,000 Sumner units of invertase activity.
33 87. A composition of matter according to 83 wherein said second enzyme is maltase, said composition of matter is in unit dosage form, and each unit dosage con tains between 100 and 100,000 units of maltase activity. 5 88. A composition of matter according to 87 wherein each unit dosage contains between 200 and 50,000 units of maltase activity. 89. A composition of matter according to 87 wherein each unit dosage contains between 500 and 20,000 units of maltase activity. 10 90. A composition of matter according to any of 83 to 89 wherein said composition of matter comprises both invertase and maltase. 91. A composition of matter according to any of 40 to 90 wherein said composition of 15 matter further comprises an additional enzyme that converts D-fructose into a molecule that is absorbed more quickly than D-fructose from the intestine into the bloodstream. 92. A composition of matter according to 91 wherein said molecule is D-glucose. 20 93. A composition of matter according to any of 40 to 92 wherein said composition of matter further comprises an additional enzyme that converts D-glucose to D fructose. 25 94. A composition of matter according to any of 91 to 93 wherein said additional enzyme is a glucose isomerase. 95. A composition of matter according to 94 wherein said composition of matter is in unit dosage form and each dosage unit contains 0.01 to 100,000 units of glu 30 cose isomerase activity per dose unit. 96. A composition of matter according to 95 wherein each dosage unit contains 0.05 to 10,000 units of glucose isomerase activity per dose unit. 35 97. A composition of matter according to 95 wherein each dosage unit contains 0.1 to 1,000 units of glucose isomerase activity per dose unit.
34 98. A composition of matter according to any of 94 to 97 wherein said glucose isom erase is a xylose isomerase. 5 99. A composition of matter according to any of 40 to 98 wherein said composition further comprises one or more members of the group consisting of lactase, al pha-amylase, beta-amylase, glucoamylase, pullulanase, isoamylase, amyloglu cosidase and cyclomaltodextrin glucantransferase (CGTase). 10 100. A composition of matter according to 99 wherein said member is lactase, said composition of matter is in unit dosage form and each dosage unit contains 50 to 200,000 FCC units of lactase activity per dose unit. 101. A composition of matter according to 100 wherein each dosage unit contains 15 100 to 100,000 FCC units of lactase activity per dose unit. 102. A composition of matter according to 101 wherein each dosage unit contains 150 to 50,000 units of lactase activity per dose unit. 20 103. A composition of matter according to any of 91 to 99 wherein said composition further comprises at least one of an electrolyte and a metal ion. 104. A composition of matter according to 103 wherein said electrolyte is selected from the group consisting of MgSO4, Na2CO3, NaHCO3, NaOH, Na2SO4, 25 MgCO3, H2SO4, NaS2O3, NaS2O5 and mixtures thereof. 105. A composition of matter according to 103 or 104 wherein said metal ion is selected from the group consisting of Mn2+, Mg2+, Ca2+, Zn2+, Fe2+, Co2+, Cu2+ and mixtures thereof. 30 106. A composition of matter according to any of 40 to 46 which is a foodstuff, and said enzyme is in active form. 107. A composition of matter according to 106 wherein the amount or concentration 35 of said enzyme in said foodstuff is greater than the naturally occurring concen tration or amount of said enzyme in said foodstuff.
35 108. A composition according to 106 or 107 wherein said foodstuff is a fructose equivalent-containing foodstuff. 5 109. A composition according to 108 wherein said foodstuff is a fructose-containing foodstuff. 110. A composition according to 108 wherein said foodstuff is a glucose-containing foodstuff. 10 111. A composition of matter according to 108 or 109 wherein said enzyme is 5-D fructose dehydrogenase which is present in an amount of 10 to 250,000 units of activity per gram of fructose in the foodstuff. 15 112. A composition of matter according to 111 wherein said 5-D-fructose dehydro genase is present in an amount of 25 and 150,000 units of activity per gram of fructose in said foodstuff. 113. A composition of matter according to 112 wherein said 5-D-fructose dehydro 20 genase is present in an amount of 50 to 100,000 units of activity per gram of fructose in said foodstuff. 114. A composition of matter according to any of 106 to 113 wherein said foodstuff is a glucose-containing foodstuff and contains glucose isomerase in an amount of 25 0.01 to 20,000 units of activity per gram of glucose in said foodstuff. 115. A composition of matter according to 114 wherein said glucose isomerase is present in an amount of 0.05 to 10,000 units of activity per gram of glucose in said foodstuff. 30 116. A composition of matter according to 115 wherein said glucose isomerase is present in an amount of 0.1 to 1,000 units of activity per gram of glucose in said foodstuff.
36 117. A composition of matter according to any of 114 to 116 wherein said enzyme is 5-D-fructose dehydrogenase which is present in an amount of 10 to 250,000 units of activity per gram of total fructose in the foodstuff. 5 118. A composition of matter according to 117 wherein said 5-D-fructose dehydro genase is present in an amount of 25 and 150,000 units of activity per gram of total fructose in said foodstuff. 119. A composition of matter according to 118 wherein said 5-D-fructose dehydro 10 genase is present in an amount of 50 to 100,000 units of activity per gram of to tal fructose in said foodstuff. 120. A composition of matter according to any of 106 to 119, wherein said foodstuff is a foodstuff which has been baked. 15 121. A composition of matter according to any of 106 to 119, wherein said foodstuff is a foodstuff which has been cooked. 122. A composition of matter according to any of 106 to 119, wherein said foodstuff 20 is a liquid, paste or broth. 123. A composition of matter according to any of 106 to 122, wherein said enzyme is present in microencapsulated form. 25 124. A composition of matter according to any of 106 to 123, wherein said enzyme is 5-D-fructose dehydrogenase. 125. A composition of matter according to any of 106 to 124, wherein said foodstuff further contains a second enzyme in active form. 30 126. A composition of matter according to 125, wherein the concentration or amount of said second enzyme in said foodstuff is greater than the naturally occurring concentration or amount of said second enzyme in said foodstuff. 35 127. A composition of matter according to 126, wherein said second enzyme is selected from the group consisting of invertase, maltase, a glucose isomerase, 37 lactase, alpha-amylase, beta-amylase, glucoamylase, pullulanase, isoamylase, amyloglucosidase and cyclomaltodextrin glucantransferase (CGTase) or a mix ture thereof. 5 128. A composition of matter according to 127 wherein said second enzyme is invertase. 129. A composition of matter according to 127, wherein said second enzyme is maltase. 10 130. A composition of matter according to 127 wherein said second enzyme is lactase. 131. A composition of matter according to 127 wherein said second enzyme is 15 alpha-amylase. 132. A composition of matter according to 127 wherein said second enzyme is beta amylase. 20 133. A composition of matter according to 127 wherein said second enzyme is glucoamylase. 134. A composition of matter according to 127 wherein said second enzyme is pullulanase. 25 135. A composition of matter according to 127 wherein said second enzyme is isoamylase. 136. A composition of matter according to 127 wherein said second enzyme is 30 amyloglucosidase. 137. A composition of matter according to 127 wherein said second enzyme is CGTase. 35 138. A compsition of matter according to 127, wherein said second enzyme is a glucose isomerase.
38 139. A composition of matter according to 138, wherein said glucose isomerase is a xylose isomerase. 5 140. A composition of matter according to 138 or 139 wherein said composition further comprises at least one of an electrolyte and a metal ion. 141. A composition of matter according to 140 wherein said electrolyte is selected from the group consisting of MgSO4, Na2CO3, NaHCO3, NaOH, Na2SO4, 10 MgCO3, H2SO4, NaS2O3, NaS2O5 and mixtures thereof. 142. A composition of matter according to 140 or 141 wherein said metal ion is selected from the group consisting of Mn2+, Mg2+, Ca2+, Zn2+, Fe2+, Co2+, Cu2+ and mixtures thereof. 15 143. A composition of matter according to any of 126 to 142, wherein said second enzyme is a mixture of at least two of the group of invertase, maltase and a glucose isomerase. 20 144. A composition of matter according to any of 126 to 142, wherein said second enzyme is a mixture of at least two of the group of invertase, maltase, a glu cose isomerase, lactase, amylase, beta-amylase, glucoamylase, pullulanase, isoamylase, amyloglucosidase and CGTase. 25 145. A composition of matter according to any of 126 to 144, wherein said second enzyme is in microencapsulated form. 146. A composition of matter according to any of 40 to 145 which comprises a mix ture of enzymes that convert D-fructose into a form that is at least one of (a) 30 biologically inactive in a chosen mammalian body, (b) not digestible in the di gestive tract of said mammalian body and (c) not metabolizable in said mam malian body. 147. A composition of matter according any of 106 to 146, wherein said composition 35 of matter is a foodstuff which is not a dough.
39 148. A composition of matter according to any of 40 to 147, wherein said enzyme that converts D-fructose into a form that is at least one of (a) biologically inac tive in a chosen mammalian body, (b) not digestible in the digestive tract of said mammalian body and (c) not metabolizable in said mammalian body is not 5 contained in an inorganic-based sol-gel biocompatible matrix. 149. A composition of matter according to any of 40 to 148 wherein said composition is substantially free of substances which are not approved for oral human in gestion. 10 150. A composition of matter according to any of 40 to 149 wherein said composition is substantially free of substances which are not approved for oral non-human mammal ingestion. 15 151. A composition of matter according to any of 40 to 150 wherein said composition of matter is adapted for oral ingestion. 152. A composition of matter according to any of 40 to 151, wherein said composi tion comprises an electron acceptor. 20 153. A composition of matter according to 152 wherein said electron acceptor is selected from the group consisting of Nicotinamide Adenine Dinucleotide+ (NAD+), nicotinamide adenine dinucleotide phosphate+ (NADP+), flavin ade nine dinucleotide+ (FAD+), vitamin C, E or A, ferricyanide, ketones, aldehydes, 25 2,6-di-chloro-phenolindophenol, phenazine methsulfate and mixtures thereof. 154. A composition of matter according to 152 or 153 wherein the molar ratio of electron acceptor to total fructose is from 1:1 to 1:1000. 30 155. A composition of matter according to 154 wherein the molar ratio of electron acceptor to total fructose is from 1:2 to 1:200. 156. A composition of matter according to 154 wherein the molar ratio of electron acceptor to total fructose is from 1:10 to 1:50. 35 40 157. A composition of matter according to 152 or 153 wherein the molar ratio of electron acceptor to fructose is from 1:1 to 1:1000. 158. A composition of matter according to 157 wherein the molar ratio of electron 5 acceptor to fructose is from 1:2 to 1:200. 159. A composition of matter according to 157 wherein the molar ratio of electron acceptor to fructose is from 1:10 to 1:50. 10 160. A composition of matter according to any of 40 to 159 which further comprises one or more enzyme stabilizers. 161. A composition according to 160 wherein said enzyme stabilizer stabilizes 5-D fructose dehydrogenase. 15 162. A composition according to 160 wherein said enzyme stabilizer stabilizes a glucose isomerase. 163. A method of treating adiposity in a mammalian subject body, comprising admin 20 istering to a mammalian subject an efficacious amount of an enzyme or a mix ture of enzymes that converts D-fructose into a form that is at least one of (a) biologically inactive in the subject body, (b) not digestible in the subject diges tive tract and (c) not metabolizable in the subject body. 25 164. A method of reducing the effect of D-fructose on a mammalian subject body, comprising administering to a mammalian subject an efficacious amount of an enzyme or a mixture of enzymes that converts D-fructose into a form that is at least one of (a) biologically inactive in the subject body, (b) not digestible in the subject digestive tract and (c) not metabolizable in the subject body. 30 165. A method of reducing the effect of total fructose on a mammalian subject body, comprising administering to a mammalian subject an efficacious amount of an enzyme or a mixture of enzymes that converts total fructose into a form that is at least one of (a) biologically inactive in the subject body, (b) not digestible in 35 the subject digestive tract and (c) not metabolizable in the subject body.
41 166. A method according to 164 or 165 wherein said mammalian subject is a human subject. 167. A method according to 164 or 165 wherein said mammalian subject is a non 5 human subject. 168. A method according to any of 164 to 167, wherein said administering comprises administering a mammalian-ingestible composition of matter according to any one of 40 to 162. 10 169. A method according to any of 164 to 168 wherein said effect of D to fructose or total fructose is adiposity. 170. A method according to any of 164 to 168 wherein said effect of D-fructose or 15 total fructose is caloric intake via fructose metabolism. 171. A method according to any of 164 to 168 wherein said effect of D-fructose or total fructose is caloric intake via glucose metabolism. 20 172. A method according to any of 164 to 168 wherein said effect of D-fructose or total fructose is selected from the group consisting of (a) weight gain (b) accel eration of weight gain (c) the prevention of weight loss and (d) a lessening of the rate of weight loss. 25 173. A method according to any of 164 to 168 wherein said effect of D-fructose or total fructose is a deleterious effect on the weight or health of said mammal. 174. A method according to 169 wherein said adiposity is treated post-facto. 30 175. A method according to 169 wherein said adiposity is reduced or prevented prophylactically. 176. A method according to any of 163 to 175, wherein said composition of matter is administered prior to eating. 35 42 177. A method according to 176, wherein said composition of matter is administered immediately prior to eating. 178. A method according to any of 163 to 175, wherein said composition of matter is 5 administered concurrently with a meal. 179. A method according to any of 163 to 175, wherein said composition of matter is administered after eating. 10 180. A method according to any of 163 to 175, wherein said composition of matter is administered immediately after eating. 181. A method according to any of 163 to 175 wherein said form is 5-keto-D fructose. 15 182. A method according to any of 163 to 181 wherein said method is used as part of a program of therapeutic or prophylactic treatment of at least one of the fol lowing, alone or attendant to adiposity: cardiovascular disease, a disease or disorder of metabolic function, a disease or disorder of hormonal function, res 20 piratory disease or disorder, disease or disorder of the hepatobiliary system, disease or disorder of the locomotor system, disease or disorder of the skin, neoplasias associated with adiposity, disorder of sexual function, psychosocial problems, reduced mobility, reduced stamina, and fatigue. 25 183. A method according to 182 wherein said cardiovascular disease is selected from the group consisting of hypertension, coronary heart disease, venous in sufficiency, heart failure, left-ventricular hypertrophy and arteriosclerosis. 184. A method according to 182 wherein said disease or disorder of metabolic 30 function is selected from the group consisting of diabetes mellitus type 1l, dyslipidemias, hyperuricemia and hyperlipoproteinemia. 185. A method according to 182 wherein said respiratory disease or disorder is sleep apnea or Pickwickan syndrome. 35 43 186. A method according to 182 wherein said disease or disorder of the hepatobil iary system is fatty liver or cholecystolithiasis. 187. A method according to 182 wherein said disease or disorder of the locomotor 5 system is selected from the group consisting of gonarthrosis, heel spur and ar throsis of the ankle joint. 188. A method according to 182 wherein said disease or disorder of the skin is selected from the group consisting of intertrigo, hirsutism an striae. 10 189. A method according to 182 wherein said neoplasias are selected from the group consisting of endometrial, mama, cervix and gall bladder carcinoma. 190. A method according to 182 wherein said disorder of sexual function is reduced 15 fertility or an increased risk of complications during birth. 191. A method according to 182 wherein said psychosocial problems are selected from the group consisting of reduced self-confidence, social isolation, discrimi nation, problems with the partner and problems at the job. 20 192. A method according to any of 163 to 191, further comprising administering to said subject a second enzyme selected from the group consisting of invertase, maltase, a glucose isomerase, lactase, alpha-amylase, beta-amylase, glucoa mylase, pullulanase, isoamylase, amyloglucosidase and cyclomaltodextrin glu 25 cantransferase (CGTase) or a mixture thereof. 193. A kit comprising an enzyme that converts D-fructose into a form that is at least one of (a) biologically inactive in a chosen mammalian body, (b) not digestible in the digestive tract of said mammalian body and (c) not metabolizable in said 30 mammalian body, or a mixture of such enzymes, and instructions explaining how to use said enzyme or mixture thereof to reduce the effects of fructose in said mammalian body. 194. A kit according to 193 wherein said instructions explain how to use said en 35 zyme or mixture thereof to reduce the effects of total fructose in said mammal ian body.
44 195. A kit according to 193 or 194 wherein said mammalian body is the human body. 196. A kit according to 193 or 194 wherein said mammalian body is a non-human 5 body. 197. A kit according to any of 193 to 196 wherein said enzyme or mixture thereof is present as a composition of matter according to any of 40 to 162. 10 198. A kit according to any of 193 to 197 wherein said enzyme or mixture of en zymes converts D-fructose into 5-keto-D-fructose. 199. A kit according to any of 193 to 198 wherein said enzyme is 5-D-fructose dehydrogenase. 15 200. A kit according to any of 193 to 198 wherein said kit further comprises a second enzyme. 201. A kit according to 200 wherein said second enzyme is selected from the group 20 consisting of invertase, maltase, a glucose isomerase, lactase, alpha-amylase, beta-amylase, glucoamylase, pullulanase, isoamylase, amyloglucosidase and cyclomaltodextrin glucantransferase (CGTase) or a mixture thereof. 202. A kit according to 201 wherein said second enzyme is a glucose isomerase. 25 203. A kit according to 201 or 202 wherein said instructions further explain how to use said second enzyme or mixture thereof in conjunction with said enzyme. 204. A kit according to 203 wherein said instructions explain how to use a mixture of 30 said second enzyme and said enzyme. 205. A reduced-total fructose foodstuff. 206. A foodstuff according to 205 which is a reduced-fructose foodstuff. 35 207. A foodstuff according to 205 or 206 which is a reduced-glucose foodstuff.
45 208. A method for preparing a reduced-total fructose foodstuff, comprising contact ing a foodstuff or foodstuff precursor with an enzyme that converts D-fructose into a form that is at least one of (a) biologically inactive in a chosen mammal 5 ian body, (b) not digestible in the digestive tract of said mammalian body and (c) not metabolizable in said mammalian body, and completing any additional steps necessary to prepare the foodstuff. 209. A method according to 208 wherein said reduced-total fructose foodstuff is a 10 reduced-fructose foodstuff. 210. A method according to 208 or 209 wherein said mammalian body is a human body. 15 211. A method according to 208 or 209 wherein said mammalian body is a non human body. 212. A method according to any of 208 to 211, wherein said enzyme is 5-D-fructose dehydrogenase. 20 213. A method according to any of 208 to 212, wherein said foodstuff is not a baked foodstuff. 214. A method according to any of 208 to 212, wherein said foodstuff is not bread. 25 215. A method according to any of 208 to 212, wherein said foodstuff is not a dough. 216. A method according to any of 208 to 215, wherein said enzyme converts D 30 fructose to 5-keto-D-fructose. 217. A method according to any of 208 to 216, wherein said method also comprises contacting said foodstuff or foodstuff precursor with a second enzyme that con verts glucose into fructose. 35 46 218. A method according to 217, wherein said second enzyme is a glucose isom erase. 219. A method according to 217 or 218, wherein said method also comprises con 5 tacting said foodstuff or foodstuff precursor with a third enzyme that cleaves glucose from saccharide chains having at least two saccharide monomers. 220. A method according to 219 wherein said third enzyme is invertase, maltase or a mixture thereof. 10 221. A method according to any of 208 to 220, wherein said method also comprises contacting said foodstuff or foodstuff precursor with an additional enzyme that cleaves fructose from saccharide chains having at least two saccharide mono mers. 15 222. A method according to any of 208 to 221 wherein said enzyme is 5-D-fructose dehydrogenase which is present in an amount of 10 to 250,000 units of activity per gram of fructose in the foodstuff. 20 223. A method according to 222 wherein said 5-D-fructose dehydrogenase is pre sent in an amount of 25 and 150,000 units of activity per gram of fructose in said foodstuff. 224. A method according to 223 wherein said 5-D-fructose dehydrogenase is pre 25 sent in an amount of 50 to 100,000 units of activity per gram of fructose in said foodstuff. 225. A method according to any of 208 to 224 wherein said foodstuff or foodstuff precursor is a glucose-containing foodstuff or foodstuff precursor and contains 30 glucose isomerase in an amount of 0.01 to 20,000 units of activity per gram of glucose in said foodstuff or foodstuff precursor. 226. A method according to 225 wherein said glucose isomerase is present in an amount of 0.05 to 10,000 units of activity per gram of glucose in said foodstuff 35 or foodstuff precursor.
47 227. A method according to 226 wherein said glucose isomerase is present in an amount of 0.1 to 1,000 units of activity per gram of glucose in said foodstuff or foodstuff precursor. 5 228. A method according to any of 225 to 227 wherein said enzyme is 5-D-fructose dehydrogenase which is present in an amount of 10 to 250,000 units of activity per gram of total fructose in the foodstuff or foodstuff precursor. 229. A method according to 228 wherein said 5-D-fructose dehydrogenase is pre 10 sent in an amount of 25 and 150,000 units of activity per gram of total fructose in said foodstuff or foodstuff precursor. 230. A method according to 229 wherein said 5-D-fructose dehydrogenase is pre sent in an amount of 50 to 100,000 units of activity per gram of total fructose in 15 said foodstuff or foodstuff precursor. 231. A method for preparing a foodstuff or foodstuff precursor having a reduced effective fructose content, comprising incorporating into said foodstuff or food stuff precursor an enzyme or mixture of enzymes that convert D-fructose into a 20 form that is at least one of (a) biologically inactive in a chosen mammalian body, (b) not digestible in the digestive tract of said mammalian body and (c) not metabolizable in said mammalian body, and completing any additional steps necessary to prepare the foodstuff, wherein said enzyme is incorporated in such manner that the enzyme will convert said D-fructose to said form after 25 ingestion of said foodstuff. 232. A method according to 231, wherein said enzyme is 5-D-fructose dehydro genase. 30 233. A method according to 231 or 232, wherein said foodstuff is not a baked food stuff. 234. A method according to 231 or 232, wherein said foodstuff is not bread. 35 235. A method according to 231 or 232, wherein said foodstuff is not a dough.
48 236. A method according to any of 231 to 235, wherein said enzyme converts D fructose to 5-keto-D-fructose. 237. A method according to any of 231 to 236 wherein said enzyme or each enzyme 5 in said mixture of enzymes is microencapsulated. 238. A method according to any of 231 to 237, further comprising incorporating into said foodstuff or foodstuff precursor a second enzyme in a manner that said additional enzyme will be active in said mammalian body after ingestion 10 therein. 239. A method according to 238 wherein said second enzyme is selected from the group consisting of invertase, maltase, a glucose isomerase, lactase, alpha amylase, beta-amylase, glucoamylase, pullulanase, isoamylase, amyloglucosi 15 dase and cyclomaltodextrin glucantransferase (CGTase) or a mixture thereof. 240. A method according to 239 wherein said second enzyme is a glucose isom erase. 20 241. A method according to 239 wherein said second enzyme is a mixture of a glucose isomerase and at least one of maltase and invertase. 242. A method according to any of 238 to 241 wherein each said additional enzyme is microencapsulated. 25 243. A method according to any of 231 to 242, further comprising incorporating into said foodstuff or foodstuff precursor an additional enzyme or mixture of en zymes that convert D-fructose into a form that is at least one of (a) biologically inactive in a chosen mammalian body, (b) not digestible in the digestive tract of 30 said mammalian body and (c) not metabolizable in said mammalian body, and completing any additional steps necessary to prepare the foodstuff, wherein said enzyme is incorporated in such manner that said additional enzyme will convert said D-fructose to said form before ingestion of said foodstuff. 35 244. A method according to 243 wherein said additional enzyme or mixture of en zymes is the same as said enzyme or mixture of enzymes.
49 245. A method according to 243 wherein said additional enzyme or mixture of en zymes is different than said enzyme or mixture of enzymes. 5 246. A method according to any of 231 to 244, further comprising incorporating into said foodstuff or foodstuff precursor a further enzyme or mixture of enzymes in a manner that said further enzyme or mixture of enzymes will be active before ingestion of said foodstuff. 10 247. A method according to 246 wherein said further enzyme is selected from the group consisting of invertase, maltase, a glucose isomerase, lactase, alpha amylase, beta-amylase, glucoamylase, pullulanase, isoamylase, amyloglucosi dase and cyclomaltodextrin glucantransferase (CGTase) or a mixture thereof. 15 248. A method according to 247 wherein said further enzyme is a glucose isom erase. 249. A method according to 246 wherein said further enzyme is a mixture of a glu cose isomerase and at least one of maltase and invertase. 20 250. A method according to any of 246 to 249, wherein said further enzyme or mixture of enzymes is the same as said second enzyme or mixture of enzymes. 251. A method according to any of 246 to 249, wherein said further enzyme or 25 mixture of enzymes is different than said second enzyme or mixture of en zymes. 252. A method according to any of 231 to 251 wherein said enzyme is 5-D-fructose dehydrogenase which is present in an amount of 10 to 250,000 units of activity 30 per gram of fructose in the foodstuff. 253. A method according to 252 wherein said 5-D-fructose dehydrogenase is pre sent in an amount of 25 and 150,000 units of activity per gram of fructose in said foodstuff. 35 50 254. A method according to 253 wherein said 5-D-fructose dehydrogenase is pre sent in an amount of 50 to 100,000 units of activity per gram of fructose in said foodstuff. 5 255. A method according to any of 231 to 254 wherein said foodstuff or foodstuff precursor is a glucose-containing foodstuff or foodstuff precursor and contains glucose isomerase in an amount of 0.01 to 20,000 units of activity per gram of glucose in said foodstuff or foodstuff precursor. 10 256. A method according to 255 wherein said glucose isomerase is present in an amount of 0.05 to 10,000 units of activity per gram of glucose in said foodstuff or foodstuff precursor. 257. A method according to 256 wherein said glucose isomerase is present in an 15 amount of 0.1 to 1,000 units of activity per gram of glucose in said foodstuff or foodstuff precursor. 258. A method according to any of 255 to 257 wherein said enzyme is 5-D-fructose dehydrogenase which is present in an amount of 10 to 250,000 units of activity 20 per gram of total fructose in the foodstuff or foodstuff precursor. 259. A method according to 258 wherein said 5-D-fructose dehydrogenase is pre sent in an amount of 25 and 150,000 units of activity per gram of total fructose in said foodstuff or foodstuff precursor. 25 260. A method according to 259 wherein said 5-D-fructose dehydrogenase is pre sent in an amount of 50 to 100,000 units of activity per gram of total fructose in said foodstuff or foodstuff precursor. 30 261. A method according to any of 231 to 260 wherein said mammalian body is a human body. 262. A method according to any of 231 to 260 wherein said mammalian body is a non-human body.

权利要求:
Claims (78)
[1] 1. A pharmaceutical composition comprising 5-D-fructose dehydrogenase in combination with one or more enzyme(s) selected from glucose isomerase, 5 invertase, lactase, maltase, alpha-amylase, beta-amylase, glucoamylase, pul lulanase, isoamylase, amyloglucosidase and cyclomaltodextrin glucanotrans ferase; but excluding pharmaceutical compositions in which the sole said en zymes present are a combination of 5-D-fructose dehydrogenase and glu cose isomerase. 10
[2] 2. A pharmaceutical composition according to claim 1 including one or more enzyme(s) protected by a coating to be stable at pH values of less than 4.
[3] 3. A pharmaceutical composition according to claim 1 or claim 2 in a form for oral administration.
[4] 4. A medical device comprising 5-D-fructose dehydrogenase in combination with 15 one or more enzyme(s) selected from glucose isomerase, invertase, lactase, maltase, alpha-amylase, beta-amylase, glucoamylase, pullulanase, isoamy lase, amyloglucosidase and cyclomaltodextrin glucanotransferase, wherein the medical device is in a form for oral administration; but excluding medical devices in which the sole said enzymes present are a combination of 5-D 20 fructose dehydrogenase and glucose isomerase.
[5] 5. A medical device according to claim 4 including one or more enzyme(s) protected by a coating to be stable at pH values of less than 4.
[6] 6. A special foodstuff comprising 5-D-fructose dehydrogenase in combination with one or more enzyme(s) selected from glucose isomerase, invertase, 25 lactase, maltase, alpha-amylase, beta-amylase, glucoamylase, pullulanase, isoamylase, amyloglucosidase and cyclomaltodextrin glucanotransferase wherein said special foodstuff is selected from foodstuffs for particular nutri tional uses, foods for special medical purposes, medical foods, food supple ments, dietary supplements, dietetic food supplements, health foods, 30 nutraceuticals and food additives; but excluding special foodstuffs in which the sole said enzymes present are a combination of 5-D-fructose dehydro genase and glucose isomerase. 52
[7] 7. The special foodstuff according to claim 6 including one or more enzyme(s) protected by a coating to be stable at pH values of less than 4.
[8] 8. The special foodstuff according to claim 6 or claim 7 in a form for oral admini stration. 5
[9] 9. A foodstuff comprising 5-D-fructose dehydrogenase, the foodstuff being selected from sweets, fruit preparations (e.g. apple puree), jam, honey, chocolate and chocolate products, baked products (e.g. biscuits and cakes), breads, pastas, vegetable dishes, potato dishes, ice cream, cereals, dairy products (e.g. fruit yoghurt and pudding), glucose containing beverages, glu 10 cose containing sauces, tomato ketchup and glucose containing sweeten ers, provided that for dishes which are cooked or baked, the 5-D-fructose dehydrogenase has been mixed into or sprinkled onto the foodstuff after cooling down.
[10] 10. The foodstuff according to claim 9 comprising 5-D-fructose dehydrogenase in 15 combination with glucose isomerase.
[11] 11. A use of 5-D-fructose dehydrogenase, optionally in combination with one or more enzyme(s) selected from glucose isomerase, invertase, lactase, mal tase, alpha-amylase, beta-amylase, glucoamylase, pullulanase, isoamylase, amyloglucosidase and cyclomaltodextrin glucanotransferase for production 20 of an agent for the curative or prophylactic treatment of adiposity.
[12] 12. The use according to claim 11, wherein adiposity is accompanied by distur bances of the cardiovascular system and/or of the metabolic and hormone based function and/or of the respiratory system and/or of the hepatobiliary system and/or disturbances of the locomotor system and/or diseases of the 25 skin and/or neoplasias and/or disorders of the sexual function and/or psy chosocial problems and/or reduced mobility and staying power and/or an in creased operation risk and/or more difficult examination conditions.
[13] 13. The use according to claim 12, wherein: (a) the disturbances of the cardiovascular system are hyperten 30 sion, coronary heart disease, venous insufficiency, heart failure, left ventricular hypertrophy and/or arteriosclerosis; or 53 (b) the disturbances of the metabolic or hormonal function are dia betes mellitus type 1l, dyslipidemias, hyperuricemia and/or hyperlipopro teinemia; or (c) the disturbances of the respiratory system are sleep apnea 5 and/or the Pickwickan syndrome; or (d) the disturbances of the hepatobiliary system are fatty liver and/or cholecystolithiasis; or (e) the disturbances of the locomotor system are gonarthrosis, heel spur and/or arthrosis of the ankle joint; or 10 (f) the disturbances of the skin are intertrigo, hirsutism and/or striae; or (g) in the case of neoplasias these are endometrial, mama, cervix and/or gall bladder carcinoma; or (h) the disorders of the sexual function are reduced fertility and/or 15 an increased risk of complications in the case of birth; or (i) the psychosocial problems are reduced self-confidence, social isolation, discrimination and/or, problems with the partner and/or at the job.
[14] 14. A use of 5-D-fructose dehydrogenase, in combination with one or more en zyme(s) selected from glucose isomerase, invertase, lactase, maltase, al 20 pha-amylase, beta-amylase, glucoamylase, pullulanase, isoamylase, amy loglucosidase and cyclomaltodextrin glucanotransferase for production of an product for (i) lowering the bioavailability of fructose and/or glucose in the human or animal body; or (ii) lowering the content of fructose and/or glucose in a foodstuff; or (iii) for lowering the usable calorie content of food; but ex 25 cluding the use of a combination consisting of the enzymes 5-D-fructose de hydrogenase and glucose isomerase for use in lowering the bioavailability of fructose and/or glucose in the human or animal body.
[15] 15. The use according to one or more of claims 11 to 14, wherein the product, preferably the pharmaceutical composition, is in a form for oral administra 30 tion; and optionally wherein the enzymes are protected by a coating to be stable at pH values of less than 4. 54
[16] 16. The use according to one or more of claims 11 to 15, according to which at least the two enzymes 5-D-fructose dehydrogenase and glucose isomerase are present.
[17] 17. A process for the treatment of a foodstuff, comprising the steps of contacting 5 the foodstuff with a 5-D-fructose dehydrogenase in combination with one or more enzyme(s) selected from glucose isomerase, invertase, lactase, mal tase, alpha-amylase, beta-amylase, glucoamylase, pullulanase, isoamylase, amyloglucosidase and cyclomaltodextrin glucanotransferase, and initiating the reduction of the fructose content and optionally the reduction of the glu 10 cose content of the foodstuff.
[18] 18. A process according to claim 17, wherein the 5-D-fructose-dehydrogenase is added to the foodstuff at the production stage thereof with the aim of devel oping its effect only after consumption of the foodstuff.
[19] 19. A mammalian-ingestible composition of matter which comprises 5-D-fructose 15 dehydrogenase and one or more members of the group consisting of lac tase, alpha-amylase, beta-amylase, glucoamylase, pullulanase, isoamylase, amyloglucosidase and cyclomaltodextrin glucantransferase (CGTase); op tionally in combination with glucose isomerase and/or invertase and/or mal tase.
[20] 20 20. A mammalian-ingestible composition of matter according to claim 19 wherein (a) said mammalian-ingestible composition of matter is a human ingestible composition of matter; or (b) said mammalian-ingestible composition of mat ter is a non-human ingestible composition of matter.
[21] 21. A composition of matter according to claim 19 or claim 20 which is (a) a 25 human dietary supplement or a pharmaceutical composition; or (b) an animal dietary supplement or a veterinary composition; and wherein said composi tion of matter optionally further comprises at least one pharmaceutically or dietarily or veterinarily acceptable carrier or excipient.
[22] 22. A composition of matter according to claim 19 or claim 20 which is a special 30 foodstuff, wherein said special foodstuff is selected from foodstuffs for par ticular nutritional uses, foods for special medical purposes, medical foods, food supplements, dietary supplements dietetic food supplements, health 55 foods, nutraceutical and food additives; and wherein said composition of matter optionally further comprises at least one pharmaceutically or dietarily acceptable carrier or excipient.
[23] 23. A composition of matter according to claim 21 or claim 22 wherein said 5 composition of matter is in the form of (a) a capsule or tablet; or (b) a gelcap.
[24] 24. A composition of matter according to claim 21 or claim 22 wherein said composition of matter is selected from (a) granules or pellets; (b) a solution; (c) a gel or suspension; (d) a liquid; (e) a powder; (e) a gel; or (f) a suspension; or (g) a powder. 10
[25] 25. A composition of matter according to claim 23 which is in the form of a capsule or tablet.
[26] 26. A composition of matter according to any of claims 21 to 25, wherein said 5 D-fructose-dehydrogenase is not contained in an inorganic-based sol-gel biocompatible matrix. 15
[27] 27. A mammalian-ingestible composition of matter according to any one of claims 19 to 26 wherein said member is lactase, and said composition of matter is in unit dosage form and: (a) each dosage unit contains 50 to 200,000 FCC units of lactase activity per dose unit; or (b) each dosage unit contains 100 to 100,000 FCC units of lactase activity per dose unit; or (c) each dosage unit 20 contains 150 to 50,000 units of lactase activity per dose unit.
[28] 28. A composition of matter according to any of claims 19 to 27 wherein: (a) the fructose dehydrogenase constitutes between 5 and 99.9% by weight of the composition of matter; or (b) the fructose dehydrogenase constitutes be tween 10 and 80% by weight of the composition of matter; or (c) the fructose 25 dehydrogenase constitutes between 25 and 60% by weight of the composi tion of matter.
[29] 29. A composition of matter according to any of claims 19 to 28, wherein said composition of matter is in unit dosage form and said unit dosage contains: (a) between 10 and 5 million units of 5-D-fructose dehydrogenase activity; or 30 (b) between 25 and 2.5 million units of 5-D-fructose dehydrogenase activity; or (c) between 50 and 1 million units of 5-D-fructose dehydrogenase activity. 56
[30] 30. A composition of matter according to any of claims 19 to 29 wherein said composition of matter comprises a coating which dissolves in an aqueous medium at a pH of between 3.0 and 8.0; and optionally: (a) said coating does not dissolve in an aqueous medium at a pH of below 3.0; or (b) said 5 coating does not dissolve in an aqueous medium at a pH below 4.0; and/or (c) said coating does not dissolve in an aqueous medium at a pH above 6.5; and/or (d) said coating does not dissolve in an aqueous me dium at a pH above 6.0.
[31] 31. A composition of matter according to any of claims 19 to 29 wherein said 10 composition of matter is a slow-release or extended-release formulation; and optionally wherein said slow-release or extended-release formulation com prises a slow-release or extended-release coating.
[32] 32. A composition of matter according to any of claims 19 to 31 wherein said composition of matter further comprises a further enzyme which is capable 15 of cleaving fructose or glucose from a sugar that contains at least two sac charide monomers.
[33] 33. A composition of matter according to claim 32 wherein said further enzyme is invertase or maltase.
[34] 34. A composition of matter according to claim 32 wherein: (a) said further en 20 zyme is invertase, said composition of matter is in unit dosage form, and (i) each unit dosage contains between 50 and 250,000 Sumner units of inver tase activity, or (ii) each unit dosage contains between 100 and 150,000 Sumner units of invertase activity, or (iii) each unit dosage contains between 150 and 100,000 Sumner units of invertase activity; or (b) said further en 25 zyme is maltase, said composition of matter is in unit dosage form, and (i) each unit dosage contains between 100 and 100,000 units of maltase activ ity or (ii) each unit dosage contains between 200 and 50,000 units of maltase activity, or (iii) each unit dosage contains between 500 and 20,000 units of maltase activity. 30
[35] 35. A composition of matter according to claim 33 or claim 34 wherein said com position of matter comprises both invertase and maltase. 57
[36] 36. A composition of matter according to any one of claims 19 to 35 wherein said composition of matter further comprises a glucose isomerase; and optionally wherein said composition of matter is in unit dosage form and: (a) each dos age unit contains 0.01 to 100,000 units of glucose isomerase activity per 5 dose unit; or (b) each dosage unit contains 0.05 to 10,000 units of glucose isomerase activity per dose unit; or (c) each dosage unit contains 0.1 to 1,000 units of glucose isomerase activity per dose unit; and further optionally wherein said glucose isomerase is a xylose isomerase.
[37] 37. A composition of matter according to claim 19 which is a foodstuff; and op 10 tionally wherein the amount or concentration of the fructose dehydrogenase in said foodstuff is greater than the naturally occurring concentration or amount of the fructose dehydrogenase in said foodstuff.
[38] 38. A composition of matter according to claim 37, wherein: (a) said foodstuff is a foodstuff which has been baked; or (b) said foodstuff is a foodstuff which has 15 been cooked; or (c) said foodstuff is a liquid, paste or broth; and/or (d) the fructose dehydrogenase is present in microencapsulated form.
[39] 39. A method for preparing a reduced-total fructose foodstuff, comprising contact ing a foodstuff or foodstuff precursor with 5-D-fructose dehydrogenase and with a second enzyme that converts glucose into fructose; and optionally 20 wherein said second enzyme is a glucose isomerase, and completing any additional steps necessary to prepare the foodstuff; and wherein: (a) said reduced-total fructose foodstuff is a reduced-fructose foodstuff; and/or (b) said foodstuff is other than a baked foodstuff; and/or (c) said foodstuff is other than bread; and/or (d) said foodstuff is other than a dough. 25
[40] 40. A method according to claim 39, wherein said method also comprises con tacting said foodstuff or foodstuff precursor with a third enzyme that cleaves glucose from saccharide chains having at least two saccharide monomers and optionally wherein said third enzyme is invertase, maltase or a mixture thereof. 30
[41] 41. A method according to claim 39 or claim 40, wherein said method also com prises contacting said foodstuff or foodstuff precursor with an additional en zyme that cleaves fructose from saccharide chains having at least two sac charide monomers. 58
[42] 42. A method for preparing a foodstuff or foodstuff precursor having a reduced effective fructose content, comprising incorporating into said foodstuff or foodstuff precursor 5-D-fructose dehydrogenase and completing any addi tional steps necessary to prepare the foodstuff, wherein said 5-D-fructose 5 dehydrogenase is incorporated in such manner that said 5-D-fructose dehy drogenase will convert D-fructose to 5-keto-D-fructose after ingestion of said foodstuff; and optionally wherein: (a) said foodstuff is other than a baked foodstuff; and/or (b) said foodstuff is other than bread; and/or (c) said food stuff is other than a dough; and/or (d) said 5-D-fructose dehydrogenase is 10 microencapsulated; and wherein said method optionally further comprises incorporating into said foodstuff or foodstuff precursor a second enzyme in a manner that said additional enzyme will be active in said mammalian body after ingestion therein; and optionally wherein said second enzyme is se lected from the group consisting of invertase, maltase, a glucose isomerase, 15 lactase, alpha-amylase, beta-amylase, glucoamylase, pullulanase, isoamy lase, amyloglucosidase and cyclomaltodextrin glucantransferase (CGTase) or a mixture thereof.
[43] 43. A method according to claim 42 wherein: (a) said second enzyme is a glu cose isomerase; or (b) said second enzyme is a mixture of a glucose isom 20 erase and at least one of maltase and invertase.
[44] 44. A method according to claim 42 or claim 43 wherein each said additional enzyme is microencapsulated.
[45] 45. A method according to any of claims 42 to 44, further comprising incorporat ing into said foodstuff or foodstuff precursor a further enzyme or mixture of 25 enzymes in a manner that said further enzyme or mixture of enzymes will be active before ingestion of said foodstuff.
[46] 46. A method according to claim 45 wherein (a) said further enzyme is selected from the group consisting of invertase, maltase, a glucose isomerase, lac tase, alpha-amylase, beta-amylase, glucoamylase, pullulanase, isoamylase, 30 amyloglucosidase and cyclomaltodextrin glucantransferase (CGTase) or a mixture thereof; or (b) said further enzyme is a glucose isomerase; or (c) said further enzyme is a mixture of a glucose isomerase and at least one of maltase and invertase; and/or (d) said further enzyme or mixture of enzymes 59 is the same as said second enzyme or mixture of enzymes; or (e) said fur ther enzyme or mixture of enzymes is different than said second enzyme or mixture of enzymes.
[47] 47. A mammalian-ingestible composition of matter which is adapted for oral 5 ingestion and comprises 5-D-fructose dehydrogenase, optionally in combina tion with a further enzyme or mixture of enzymes selected from invertase, maltase, a glucose isomerase, lactase, alpha-amylase, beta-amylase, glu coamylase, pullulanase, isoamylase, amyloglucosidase and cyclomaltodex trin glucantransferase (CGTase) or a mixture thereof; wherein the composi 10 tion of matter is in the form of: (a) a tablet; or (b) granules; or (c) a powder; or (d) a liquid other than a foodstuff; or 15 (e) a gel.
[48] 48. A mammalian-ingestible composition of matter according to claim 47 which is in liquid form and wherein the liquid form is a solution.
[49] 49. A mammalian-ingestible composition of matter according to claim 47 which is in liquid form and wherein the liquid form is in the form of drops. 20
[50] 50. A mammalian-ingestible composition of matter according to claim 47 which is in liquid form and wherein the liquid form is a suspension.
[51] 51. A mammalian-ingestible composition of matter according to claim 47 which is in powder form and is packaged in single dosage amounts.
[52] 52. A mammalian-ingestible composition of matter according to claim 51 wherein 25 the single dosage amount is packaged in single bags.
[53] 53. A mammalian-ingestible composition of matter according to claim 47 which is in powder form and is provided in a dosing dispenser. 60
[54] 54. A mammalian-ingestible composition of matter which comprises 5-D-fructose dehydrogenase and wherein said composition of matter is an animal dietary supplement or a veterinary composition.
[55] 55. A composition of matter according to claim 54 which further comprises at 5 least one veterinarily acceptable carrier or excipient.
[56] 56. A composition of matter according to claim 54 or 55 wherein said composition of matter contains said enzyme in microencapsulated form.
[57] 57. A composition of matter according to any of claims 54 to 56 wherein said composition of matter is in the form of (a) a capsule or tablet; or (b) granules 10 or pellets; or (c) a solution; or (d) a liquid; or (e) a gel or suspension; or (f) a gelcap; or (g) a powder.
[58] 58. A composition of matter according to any of claims 54 to 57 wherein the 5-D fructose dehydrogenase constitutes (a) between 5 and 99.9% by weight of the composition of matter; or (b) between 10 and 80% by weight of the com 15 position of matter; or (c) between 25 and 60% by weight of the composition of matter.
[59] 59. A composition of matter according to any of claims 54 to 57, wherein said composition of matter is in unit dosage form and said unit dosage contains (a) between 10 and 5 million units of 5-D-fructose dehydrogenase activity; or 20 (b) between 25 and 2.5 million units of 5-D-fructose dehydrogenase activity; or (c) between 50 and 1 million units of 5-D-fructose dehydrogenase activity.
[60] 60. A composition of matter according to any of claims 54 to 59 wherein said composition of matter comprises a coating which dissolves in an aqueous medium at a pH of between 3.0 and 8.0. 25
[61] 61. A composition of matter according to any of claims 54 to 60 wherein said composition of matter is a slow-release or extended-release formulation; for example wherein said slow-release or extended-release formulation com prises a slow-release or extended-release coating.
[62] 62. A composition of matter according to any of claims 54 to 61 wherein said 30 composition of matter further comprises a second enzyme. 61
[63] 63. A composition of matter according to claim 62 wherein said second enzyme is capable of cleaving fructose or glucose from a sugar that contains at least two saccharide monomers.
[64] 64. A composition of matter according to claim 64 wherein said second enzyme 5 is invertase or maltase.
[65] 65. A composition of matter according to any of claims 55 to 66 wherein said composition of matter further comprises an additional enzyme that converts D-glucose to D-fructose, and said additional enzyme is a glucose isomerase.
[66] 66. A composition of matter according to claim 67 wherein said glucose isom 10 erase is a xylose isomerase.
[67] 67. A composition of matter according to any of claims 55 to 68 wherein said composition further comprises one or more members of the group consisting of lactase, alpha-amylase, beta-amylase, glucoamylase, pullulanase, isoa mylase, amyloglucosidase and cyclomaltodextrin glucantransferase 15 (CGTase).
[68] 68. A composition of matter according to claim 54 which is a foodstuff.
[69] 69. A composition of matter according to claim 68 wherein the amount or concen tration of said enzyme in said foodstuff is greater than the naturally occurring concentration or amount of said enzyme in said foodstuff. 20
[70] 70. A method of treating adiposity in a mammalian subject body, comprising administering to a mammalian subject an efficacious amount of 5-D-fructose dehydrogenase.
[71] 71. A method of reducing the effect of D-fructose on a mammalian subject body, comprising administering to a mammalian subject an efficacious amount of 25 5-D-fructose dehydrogenase.
[72] 72. A method of reducing the effect of total fructose on a mammalian subject body, comprising administering to a mammalian subject an efficacious amount of 5-D-fructose dehydrogenase.
[73] 73. A method according to claim 71 or claim 72 wherein said effect of D-fructose 30 or total fructose is selected from the group consisting of (a) weight gain (b) 62 acceleration of weight gain (c) the prevention of weight loss and (d) a less ening of the rate of weight loss.
[74] 74. A method according to claim 71 or claim 72 wherein said effect of D-fructose or total fructose is adiposity. 5
[75] 75. A method according to claim 71 or claim 72 wherein said effect of D-fructose or total fructose is caloric intake via fructose metabolism.
[76] 76. A method according to claim 71 or claim 72 wherein said effect of D-fructose or total fructose is caloric intake via glucose metabolism.
[77] 77. A composition of matter comprising the enzyme 5-D-fructose dehydrogenase 10 admixed with a mammalian-ingestible substance wherein said 5-D-fructose de hydrogenase is microencapsulated.
[78] 78. The use of 5-D-fructose dehydrogenase in combination with one or more en zyme(s) selected from glucose isomerase, invertase, lactase, maltase, alpha amylase, beta-amylase, glucoamylase, pullulanase, isoamylase, amyloglucosi 15 dase and cyclomaltodextrin glucanotransferase for lowering the usable calorie content of food.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US10568942B2|2020-02-25|Agent for use in the case of fructose intolerance

---

US10624954B2|2020-04-21|Agent for reducing the useable calorie content of food and for therapeutic reduction of weight, in particular for use in the case of adiposity |

---

CA2890721C|2018-01-09|Agent for use in the case of fructose intolerance

---

US9415093B2|2016-08-16|Agent for use in the case of disorders of blood sugar metabolism, including diabetes

---

US20090214620A1|2009-08-27|Agent for use in the case of disorders of blood sugar metabolism, including diabetes

---

AU2013211517B2|2016-06-30|Agent for reducing the useable calorie content of food and for therapeutic reduction of weight, in particular for use in the case of adiposity |

---

ES2707785T3|2019-04-05|Agent to reduce the usable calorie content of food and for the therapeutic reduction of weight, in particular for use in the case of adiposity |

---

AU2013273733B2|2015-12-24|Agent for use in the case of fructose intolerance

---

NZ569117A|2011-11-25|Agent comprising 5-D-fructose dehydrogenase for use in the case of fructose intolerance

同族专利:

---

公开号 | 公开日

---

AU2013211517B2|2016-06-30|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

WO1999057986A1|1998-05-13|1999-11-18|Novo Nordisk Biotech, Inc.|Methods for using dehydrogenases in baking|

---

US6395299B1|1999-02-12|2002-05-28|Biostream, Inc.|Matrices for drug delivery and methods for making and using the same|

---

WO2007057749A2|2005-11-16|2007-05-24|Pro Natura Gesellschaft für gesunde Ernährung mbH|Agent for use in the case of fructose intolerance|

---

法律状态:
2016-10-27| FGA| Letters patent sealed or granted (standard patent)|

优先权:

---

申请号 | 申请日 | 专利标题

---

DE102005056170.5||2005-11-23||

---

DE102005060767.5||2005-12-16||

---

DE102005061330.6||2005-12-20||

---

DE102005063194.0||2005-12-30||

---

DE102006001016.7||2006-01-05||

---

US60/757,413||2006-01-10||

---

DE102006013623.3||2006-03-22||

---

DE102006014420.1||2006-03-27||

---

US60/831,173||2006-07-17||

---

AU2006316815A|AU2006316815A1|2005-11-23|2006-11-23|Agent for reducing the useable calorie content of food and for therapeutic reduction of weight, in particular for use in the case of adiposity |

---

AU2013211517A|AU2013211517B2|2005-11-23|2013-08-01|Agent for reducing the useable calorie content of food and for therapeutic reduction of weight, in particular for use in the case of adiposity |AU2013211517A| AU2013211517B2|2005-11-23|2013-08-01|Agent for reducing the useable calorie content of food and for therapeutic reduction of weight, in particular for use in the case of adiposity |